Abstract—Cardiovascular disease remains the principal cause of death and disability among patients with diabetes mellitus. Diabetes mellitus exacerbates mechanisms underlying atherosclerosis and heart failure. Unfortunately, these mechanisms are not adequately modulated by therapeutic strategies focusing solely on optimal glycemic control with currently available drugs or approaches. In the setting of multifactorial risk reduction with statins and other lipid-lowering agents, antihypertensive therapies, and antihyperglycemic treatment strategies, cardiovascular complication rates are falling, yet remain higher for patients with diabetes mellitus than for those without. This review considers the mechanisms, history, controversies, new pharmacological agents, and recent evidence for current guidelines for cardiovascular management in the patient with diabetes mellitus to support evidence-based care in the patient with diabetes mellitus and heart disease outside of the acute care setting. (Circulation. 2016;133:2459–2502. DOI: 10.1161/CIRCULATIONAHA.116.022194.)

Key Words: cardiovascular diseases diabetes mellitus drugs heart failure trials

Reducing atherosclerotic cardiovascular disease (ASCVD) burden in diabetes mellitus is a major clinical imperative that should be prioritized to reduce premature death, improve quality of life, and lessen individual and economic burdens of associated morbidities, decreased work productivity, and high cost of medical care. Atherosclerotic cardiovascular disease remains the principal cause of death and disability among patients with diabetes mellitus, especially in those with type 2 diabetes mellitus in whom it typically occurs 14.6 years earlier,1 with greater severity, and with more diffuse distribution than in individuals without diabetes mellitus.2,3 Furthermore, about two-thirds of deaths in people with diabetes mellitus are attributable to cardiovascular disease: of these, ≈40% are from ischemic heart disease, 15% from other forms of heart disease, principally congestive heart failure, and ≈10% from stroke. Among those with diabetes mellitus, excess risks of death from any cause and of ASCVD mortality are particularly prominent in those with younger age, higher burden of glycemia, and greater renal complications, in comparison with those without.4 Although the incidences of diabetes mellitus–related complications including cardiovascular disease have decreased over the past 2 decades, patients with diabetes mellitus continue to have significantly increased risk for vascular complications in comparison with individuals without diabetes mellitus (Figure 1).5 An estimated 382 million people worldwide have diabetes mellitus, and this number is expected to reach 592 million by the year 2035,6 underscoring the global impact of ASCVD in diabetes mellitus.

Key manifestations of ASCVD in diabetes mellitus include advanced atherosclerosis manifest as coronary heart disease, ischemic stroke, peripheral artery disease, and heart failure. Understanding the mechanisms, strategies for and challenges with managing ASCVD and heart failure risk in diabetes mellitus, as well as the potential cardiovascular risks and benefits of glucose-lowering drugs, is important for managing cardiovascular disease in diabetes mellitus. In this clinical update, we review the current understanding of the mechanisms of ASCVD and heart failure in diabetes mellitus, management of these cardiovascular conditions in the diabetes mellitus population, and special considerations for treatment of diabetes mellitus in patients with ASCVD or heart failure. We discuss evidence-based management and areas of uncertainty for ischemic heart disease and heart failure therapies in type 2 diabetes mellitus, as well as the impact of diabetes mellitus medications on cardiovascular risks. A structured review of the published literature, involving searches of English-language manuscripts for clinical trials and meta-analyses of those trials that may inform treatment decisions for each section was performed by the authors. Case series and nonrandomized trials were not considered for inclusion.

Epidemiology of ASCVD in Diabetes Mellitus

The high prevalence of coronary and peripheral artery disease in individuals with diabetes mellitus has been recognized for more than a century,7–9 yet the ability to improve cardiovascular event rates by glucose lowering per se has remained elusive.
In the landmark Framingham Heart Study published in 1979, Kannel and McGee first prospectively demonstrated a higher incidence of cardiovascular disease across all age groups for individuals with diabetes mellitus (defined at the time by random blood glucose of ≥150 mg/dL [8.3 mmol/L]) compared with those without, with an even greater impact of diabetes mellitus on cardiovascular morbidity and mortality for women than for men. The increased risk for ASCVD in diabetes mellitus could not be fully accounted for by associated traditional cardiovascular risk factors, and the presence of diabetes mellitus in conjunction with other risk factors appeared to cause a synergistic rather than additive additional risk. Importantly, the observed effect of diabetes mellitus on ASCVD risk was potentially underestimated in the Framingham Heart study, which also included persons with abnormal glucose tolerance (defined then as a random blood glucose >120 mg/dL).

Subsequent studies confirmed the importance of diabetes mellitus as an ASCVD risk factor in diverse populations and suggested diabetes mellitus as a risk equivalent for established coronary heart disease, although this remains somewhat controversial. Persons with diabetes mellitus but without a previous myocardial infarction were demonstrated to have high risk of myocardial infarction (20.2% incidence over 7 years), similar to that of individuals with a previous myocardial infarction but no diabetes mellitus as shown in the East–West study conducted within the Finnish population. Likewise, comparable hazard ratios for cardiovascular death were found in persons age ≥30 years with diabetes mellitus requiring glucose-lowering medications but without previous myocardial infarction in comparison with persons with a previous myocardial infarction, among 3.3 million individuals from Denmark including 71,801 with diabetes mellitus and 79,575 with previous myocardial infarction but without diabetes mellitus. Furthermore, 21% of all deaths among Alaska Natives with diabetes mellitus are from ischemic heart disease. Taken together across multiple populations, these studies support the designation of diabetes mellitus as a risk equivalent for coronary heart disease and highlight the need to better understand ASCVD and to optimize treatment among patients with diabetes mellitus.

**Mechanisms of Increased ASCVD Risk and Mortality in Type 2 Diabetes Mellitus**

Multiple cellular and molecular pathophysiologic factors participate in ASCVD, creating the “perfect storm” for atherosclerosis. Patients with type 2 diabetes mellitus have greater atherosclerotic plaque burden, higher atheroma volume, and smaller coronary artery lumen diameter than persons without diabetes mellitus. A general overview of atherogenesis, atherosclerosis progression, and atherothrombosis in diabetes mellitus is presented in graphic form in Figure 2. Although numerous processes may contribute to ASCVD in diabetes mellitus, only the following will be described to provide therapeutic context: hyperglycemia, insulin resistance or hyperinsulinemia, dyslipidemia, inflammation, reactive oxygen species, endothelial dysfunction, hypercoagulability, and vascular calcification. This discussion is intended to provide a framework for the review of clinical trial evidence and thus is not comprehensive.

**Role of Hyperglycemia**

Diabetes mellitus is diagnosed based on fasting plasma glucose ≥126 mg/dL (7.0 mmol/L), 2-hour glucose after 75-g oral glucose load ≥200 mg/dL (11.1 mmol/L), hemoglobin A1c (HbA1c) ≥6.5% (48 mmol/mol), or random plasma glucose ≥200 mg/dL confirmed by repeat testing in the absence of signs or symptoms of hyperglycemia or hyperglycemic crisis. Diabetes mellitus is a heterogeneous disorder with hyperglycemia required for its diagnosis, and despite markedly different genetic and mechanistic causes, both type 1 and type 2 diabetes mellitus are associated with higher prevalence of ASCVD. Therefore, it is natural to consider hyperglycemia among the causes for accelerated ASCVD observed in patients with diabetes mellitus.

Abundant epidemiological data support the association between hyperglycemia and increased cardiovascular risk. There is strong evidence demonstrating greater risk for ASCVD with increasing dysglycemia, with an estimated 11% to 16% increase in cardiovascular events for every 1% increase in HbA1c. The Swedish National Diabetes Register provided compelling evidence for HbA1c as a predictor of fatal and nonfatal coronary heart disease, fatal and nonfatal stroke, fatal and nonfatal cardiovascular disease, fatal cardiovascular disease, and total mortality in a study of 18,334 persons with type 2 diabetes mellitus followed over a mean of 5.6 years. The relationship between HbA1c and macrovascular disease appears linear and not J-shaped and is observed in subgroups of patients with shorter (≤7 years) and longer duration of diabetes mellitus, previous history of cardiovascular disease, and different types of glycemic therapy (oral hypoglycemia agent...
or insulin). Likewise, a 12% increase in ASCVD risk for every 18 mg/dL (1 mmol/L) increase in fasting glucose >105 mg/dL and a similar 13% increased hazard ratio for vascular death for every 18-mg/dL increase in fasting serum glucose >100 mg/dL (5.6 mmol/L) was demonstrated by the Emerging Risk Factors Collaboration group, with comparable findings in numerous studies.

In vitro studies and in vivo models in which hyperglycemia is induced in the absence of elevated lipids are consistent with a direct effect of hyperglycemia on endothelial dysfunction, atherosclerotic lesion severity and complexity, and plaque burden. A commonly used preclinical diabetes mellitus model involves streptozotocin-treatment, which is toxic to pancreatic β-cells, in an atherosclerosis-prone animal such as a low-density lipoprotein (LDL)-receptor or apolipoprotein (apo)-E deficient mouse. Hyperglycemia results in atherosclerotic lesion formation which can be prevented by intensive insulin therapy, while accelerated atherosclerosis develops in the setting of hypercholesterolemia. Similarly, pigs develop atherosclerotic lesions closely mimicking those observed in humans when fed a high-fat high cholesterol diet after streptozotocin-induced diabetes mellitus, developing accelerated atherosclerosis in the aorta and coronary arteries with complex lesions, hemorrhage, and calcification.

Acute hyperglycemia can attenuate endothelial function and reduce nitric oxide (NO) bioavailability while increasing...
endothelial cell leukocyte adhesion, mediated in part by increased oxidative stress and inflammation. Increased flux through the aldose reductase pathway, synthesis of diacylglycerol with protein kinase C activation, and production of advanced glycation end-products (AGE) contribute to activation of endothelial cell receptor for AGEs. Vascular smooth muscle cells (VSMC) undergo phenotypic switching from a quiescent, contractile state to an activated, proliferative, migratory, dedifferentiated state in the setting of hyperglycemia. High glucose concentrations lead to macrophage inflammation and enhancement of response to inflammation, and even transient hyperglycemia leads to epigenetic changes with activation of the nuclear factor-κ-light-chain-enhancer of activated B cells (NF-κB) pathway that persists even after return to normoglycemia. Under experimental conditions to simulate glycemic variability in individuals with diabetes mellitus, 6 hours of hyperglycemia alternating with normoglycemia within a 24-hour period promotes worsening of endothelial function and increased oxidative stress as compared with continuous hyperglycemia even at serum glucose concentrations as high as 282 mg/dL (15.6 mmol/L). Together these represent distinct and overlapping mechanisms by which hyperglycemia can promote atherogenesis and accelerate the progression of atherosclerosis (Figure 2).

Role of Insulin Resistance/Hyperinsulinemia

Epidemiological evidence strongly associates insulin resistance with cardiovascular risk in humans. People with insulin resistance have higher rates of hypertension, dyslipidemia, and impaired glucose tolerance, which contribute to development, progression, and complexity of atherosclerosis. Impairment of insulin signaling at multiple points in the insulin signaling pathway in endothelial cells, VSMC, and macrophages promotes development and progression of atherosclerosis, as does the proinflammatory state induced in insulin resistance (Figure 2).

Both systemic and tissue-specific vascular insulin resistance contribute to atherosclerosis development and plaque vulnerability. In type 2 diabetes mellitus, there is selective impairment of insulin signaling through phosphoinositide 3-kinase/protein kinase B, which mediates the metabolic effects of insulin to maintain normal glucose metabolism, whereas signaling via the extracellular signal-regulated mitogen-activated protein kinase pathway generally remains intact. Compensatory hyperinsulinemia overstimulates the extracellular signal-regulated mitogen-activated protein kinase pathway, promoting development or progression of atherosclerosis.

Role of Diabetes Mellitus Dyslipidemia

Diabetes mellitus and dyslipidemia commonly occur together, with lipid abnormalities affecting 60% to 70% of type 2 diabetes mellitus, and hyperglycemia accelerates atheroma formation in the setting of diabetic dyslipidemia. LDL cholesterol particles are more atherogenic in diabetes mellitus even in the absence of overt increased LDL concentration, with small, dense particles that are particularly prone to modification. Diabetic dyslipidemia is also characterized by elevated triglycerides, low high-density lipoprotein (HDL) cholesterol, and higher concentrations of apoB-containing particles. Mechanisms underlying diabetic dyslipidemia remain incompletely understood. Lipid changes are observed in insulin-resistant persons with normal glucose tolerance and in those with metabolic syndrome years before clinical diagnosis of type 2 diabetes mellitus, suggesting either coassociations of independent disorders or a pathophysiological role for insulin resistance, rather than hyperglycemia, in the development of diabetic dyslipidemia.

Metabolism of very-low-density lipoprotein (VLDL), the main transporter for fasting triglycerides, is insulin-regulated at multiple levels. Insulin suppresses lipolysis and regulates circulating free fatty acids, which are substrates for VLDL cholesterol assembly and secretion. In the liver, insulin mediates transfer of triglycerides to apoB and regulates lipoprotein lipase activity to delipidate VLDL cholesterol. Lipoprotein lipase activity can be disrupted by increased circulating free fatty acids and inhibited by apoCIII, whereas apoCIII hinders hepatic uptake of triglyceride-rich lipoproteins, and is itself inhibited by insulin. Thus, in the insulin-resistant state, hypertriglyceridemia may be a consequence of elevated free fatty acid level and decreased degradation of apoB leading to overproduction of VLDL cholesterol, impaired lipoprotein lipase.
activity, and decreased hepatic uptake of VLDL with reduced VLDL cholesterol clearance.

Other lipid abnormalities observed in diabetes mellitus can be attributed in part to elevated triglycerides. The transfer of triglycerides from triglyceride-rich lipoproteins to HDL and LDL cholesterol is facilitated by cholesteryl ester transfer protein (CETP). Hypertriglyceridemia stimulates CETP activity, resulting in HDL and LDL cholesterol with high triglyceride content. Enrichment with triglycerides makes HDL particles subject to increased catabolism, lowering plasma HDL cholesterol concentration, whereas triglyceride-enriched LDL particles undergo hydrolysis, decreasing particle size.

Elevated free fatty acids impair insulin signaling and cause subclinical inflammation with subsequent pancreatic β-cell dysfunction. Free fatty acid elevation may also be involved in terminal arrhythmias and induction of a prothrombotic state. The CETP inhibitor torcetrapib raises HDL cholesterol concentration but also improves hyperglycemia. Furthermore, recombinant HDL cholesterol infusions improve glucose dysregulation in patients with type 2 diabetes mellitus. These data suggest a role for HDL cholesterol in glucose metabolism. Proposed mechanisms include anti-inflammatory properties of HDL cholesterol and the central role of HDL cholesterol in mediating reverse cholesterol transport, or cholesterol efflux, which may subsequently improve insulin sensitivity or secretion. Recent investigations suggest a role for impaired HDL function with decreased cholesterol efflux capacity in diabetes mellitus. However, to date pharmacological means to raise HDL cholesterol levels have not been associated with both glucose lowering and improved cardiovascular outcomes, as discussed below in the section on nonstatin lipid lowering trials.

**Role of Inflammation**

Parallel epidemics of obesity, diabetes mellitus, and ASCVD suggest common molecular mechanisms for these diseases and novel therapeutic targets. Increased inflammatory markers and mediators are found in obesity, with increasing numbers of components of the metabolic syndrome, and predict incident hypertension, type 2 diabetes mellitus, and cardiovascular event rates. High-sensitivity C-reactive protein, a marker of inflammation, adds cardiovascular prognostic information beyond traditional risk factors in all major cohorts evaluated.

Hyperlipidemia within the atherosclerotic plaque results in recruitment and migration of monocytes and other immune and inflammatory cells into the vascular subendothelial layer. Recruited monocytes differentiate into macrophages or dendritic cells. Activated macrophages express scavenger receptors to facilitate engulfment of both native and oxidized low density lipoprotein, forming foam cells which, along with other inflammatory cells, increase production of chemokines and cytokines. These mechanisms operate in a feed-forward cycle, promoting atherosclerotic lesion progression within the inflammatory milieu. Atherosclerotic lesions contain T cells in addition to macrophages, but T cells from individuals with diabetes mellitus have been found to have a predominance of the proinflammatory Th-1 phenotype. In addition to deleterious effects of LDL on macrophage and foam cells, cholesterol crystals themselves within the atherosclerotic lesion can activate the neuronal apoptosis inhibitor protein (NAIP), leucine-rich repeat (LRR), and pyrin domain (PYD) domains-containing protein 3 NALP3, also known by NALP3 inflammasome complex. This results in increased transcription of both NF-kB-regulated gene products and interleukin-1β provides an additional feed forward mechanism to amplify the deleterious effects of cholesterol particles that have accumulated in lipid rich plaque, which may participate in the accelerated atherosclerosis of diabetic dyslipidemia.

In addition to the interleukin-1β signaling pathway, diverse other cellular stress pathways (including tumor necrosis factor-α, oxidized LDL, the receptor for advanced glycation end-products [RAGE], reactive oxygen species [ROS], members of the protein kinase C enzyme family, and endoplasmic reticulum stress), many of which are increased in diabetes mellitus, can all activate the NF-kB transcription factor pathway. NF-kB in turn regulates expression of proatherogenic molecules including surface proteins, cytokines, and chemokines. Inhibiting this pathway attenuates the development of atherosclerosis in murine models. However, in vivo studies yield conflicting results with some proatherogenic and some anti-atherogenic effects, indicating the pathway has complex roles in atherosclerosis.

Whether targeting inflammation per se will reduce cardiovascular event rates is under investigation in multiple large scale clinical trials with diverse agents, including targeting of interleukin-1β with the monoclonal antibody canakinumab, tumor necrosis factor-α using etanercept, interleukin-6 using tocilizumab, interleukin-1 receptor with anakinra, and multiple inflammatory targets including the nucleotide-binding leucine-rich repeat-containing pyrin receptor 3 inflammasome with colchicine or multiple targets with low-dose methotrexate. Low-dose methotrexate has been reported to reduce cardiovascular event rates by 20% or more in patients with rheumatoid arthritis or psoriatic arthritis. Additional ongoing investigations target alternative inflammatory pathways including oxidized LDL cholesterol, lipoprotein-associated phospholipase A2, secretory phospholipase A2, P-selectin, and leukotrienes, among others. Given the complexity of the interactions between the inflammatory, metabolic, and vascular pathways, future studies will need to address the clinical benefits of modulating these individual pathways as well as their inter-relationships.

**Role of Reactive Oxygen Species**

ROS and reactive nitrogen species (RNS) are primarily produced through activity of the electron transport chain in mitochondria, and by other pathways including xanthine oxidase, lipoxygenase, myeloperoxidase and NO synthase. Alterations in electron transport chain activity result in increased electrochemical gradients and free radical leakage. Inactivation and degradation of ROS/RNS are regulated by complex networks of proteins and signaling pathways including superoxide dismutase, catalase, glutathione peroxidase, peroxiredoxins, and thioredoxins. ROS/RNS participate in compartmentalized signaling pathways that are essential for normal cardiovascular physiology. However, excess ROS/RNS from mitochondrial injury, abnormal vascular hemodynamics, or hyperglycemia
leads to oxidative stress, with increased cell proliferation, migration, endoplasmic reticulum stress, autophagy, senescence, and necrosis. This is manifest as hypertension from vascular endothelial dysfunction, reperfusion injury in patients with underlying occlusive atherosclerosis, and accelerated atherosclerosis. Hyperglycemia causes increased production of ROS via formation of Amadori products, which are oxidized to form AGEs that in turn activate RAGE to stimulate NADPH oxidase-1 with intracellular ROS production.

Role of Endothelial Dysfunction

Endothelial function is attenuated in both type 1 and type 2 diabetes mellitus. Even short exposure to high glucose concentrations is sufficient to reduce NO bioavailability and endothelial dependent vasodilation. Endothelial dysfunction may be an independent risk marker for cardiovascular events. Dysfunctional endothelium promotes leukocyte and platelet adhesion, thrombosis, and inflammation. Insulin stimulates endothelial NO synthase–induced production of NO by endothelial cells via the PI3-kinase/Akt pathway, and defects along the insulin signaling pathway seen in insulin resistance and diabetes mellitus result in decreased endothelial NO synthase activity and decreased NO production, promoting endothelial dysfunction. Production of the vasoconstrictors endothelin-1 and angiotensin II are increased in the presence of compensatory hyperinsulinemia and contribute further to endothelial dysfunction and hypertension. Patients with type 2 diabetes mellitus also have abnormal VSMC function and ROS/RNS, which exacerbate diabetes mellitus–associated endothelial dysfunction.

Role of Hypercoagulability

Patients with diabetes mellitus are at increased risk for recurrent atherothrombosis. Experimentally-induced hyperinsulinemia and hyperglycemia results in elevated circulating tissue factor procoagulant activity and other prothrombotic proteins. Patients with diabetes mellitus are more thrombogenic and have elevated concentrations of plasminogen activator-inhibitor-1 antigen, von Willebrand factor–antigen, and fibrinogen, which are exacerbated by poor glycemic control. Higher concentrations of coagulation factor II, VII, VIII, and lower anticoagulant (protein C) are also related to blood glucose concentration. These prothrombotic processes may contribute to atherothrombosis in diabetes mellitus, and a recent trial using the thrombin receptor antagonist vorapaxar for secondary prevention of ASCVD in diabetes mellitus demonstrated lower major vascular events rates.

Role of Vascular Calcification

Individuals with diabetes mellitus are more likely to have calcified atherosclerotic lesions, which occur in more advanced, complex atherosclerotic lesions. Coronary calcium score as measured by electron-beam computed tomography is an independent risk factor for cardiovascular events and all-cause mortality in persons with or without diabetes mellitus. Individuals with diabetes mellitus have higher coronary artery calcification scores than those without diabetes mellitus and calcified plaque burden similar to that of older individuals without diabetes mellitus. In addition, persons with diabetes mellitus are at particular risk of developing peripheral artery disease with a predilection for the distal tibial artery circulation. Tibial artery calcification is associated with increased risk of limb amputation and all-cause mortality. Underlying mechanisms for this may be related to the role of hyperglycemia with development of AGEs which accelerate vascular calcification. Hyperglycemia also leads to increased post-translational protein modification, including modification by O-linked N-acetylglucosamine (O-GlcNAc). O-Glc-N-acetyl starts a cascade of proatherogenic pathways which potentiates vascular calcification. In addition, altered regulation of osteoprotegerin and osteocalcin may promote arterial calcification in diabetes mellitus. Lastly, as noted above, diabetes mellitus is associated with arterial inflammation with increased levels of tumor necrosis factor-alpha, which is a mediator of arterial calcification.

Atherosclerotic Cardiovascular Risk Reduction in Diabetes Mellitus

Targeting individual cardiovascular risk factors reduces ASCVD risk in diabetes mellitus, but addressing multiple risk factors simultaneously may synergistically reduce cardiovascular event risk even further. This hypothesis is supported by the Steno-2 study, in which 160 participant with type 2 diabetes mellitus and albuminuria were randomized to intensive versus conventional control of glycemia, blood pressure, and lipids, and followed for a mean of 7.8 years. The trial showed a statistically and clinically significant 53% reduction (hazard ratio [HR], 0.47; 95% confidence interval [CI], 0.24–0.73) for the primary composite cardiovascular event end point. Cardiovascular risk differences between intensive and conventional therapy separated after 1 year. The number needed-to-treat was 5 over 7.8 years to achieve this magnitude of ASCVD risk reduction. The Steno-2 trial was not designed to identify which interventions were most effective, but use of statin and antihypertensive drugs may have accounted for much of the cardiovascular benefit. A secondary analysis of the Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes (BARI-2D) trial evaluating multiple interventions also supports concurrent risk factor control lowers total mortality and the composite of death, myocardial infarction, and stroke in patients with type 2 diabetes mellitus and established coronary heart disease. These findings must be interpreted with caution, as the trial was not conducted with randomization to multifactorial control, but BARI-2D demonstrates not only improved cardiovascular outcomes among those who achieved control of multiple risk factors using a comprehensive approach, but also the feasibility of protocol-guided multi-risk factor targeted intensive medical therapy. While achievement of multiple treatment goals in diabetes mellitus care has improved over time, currently only 14.3% of US adults with type 2 diabetes mellitus are at recommended goals for HbA1c, blood pressure, and LDL cholesterol.

Evidence for ASCVD risk reduction in diabetes mellitus by addressing risk factors individually from clinical trials of lipid lowering, blood pressure-lowering, aspirin therapy, lifestyle, and glucose-lowering therapies is presented below, beginning with risk factors having the strongest evidence to date for ASCVD risk reduction in diabetes mellitus.
Lipid-Lowering Therapy
There is strong high level evidence from randomized clinical trials that lipid-lowering therapy with 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) reduces ASCVD event rates in diabetes mellitus, with some benefits potentially attributable to nonlipid-lowering, anti-inflammatory effects of statins.134,179–182 The most recent American College of Cardiology/American Heart Association guidelines recognize patients with diabetes mellitus between the ages of 40 and 75 years as 1 of the 4 principal groups to benefit from statins and recommend treatment with a moderate-intensity statin or a high-intensity statin for individuals with a ≥7.5% 10-year risk of cardiovascular disease.132 In those <40 or >75 years of age, guidelines recommend individualizing statin therapy based on the benefits of ASCVD risk reduction versus the potential for adverse effects, interactions with other drugs, and patient preference.132

These recommendations are based on multiple lines of evidence. Statin lowering of LDL cholesterol levels by 39 mg/dL (1 mmol/L) in high-risk individuals reduces coronary mortality risk 19%, as demonstrated in a meta-analysis by the Cholesterol Treatment Trials’ Collaboration. Magnitude of mortality benefits were similar for those with or without diabetes mellitus as seen in subgroup analyses.183 A 21% reduction in major vascular events occurred per 1-mmol/L reduction in LDL cholesterol, irrespective of prior history of vascular disease, gender, age, body mass index (BMI), or baseline systolic or diastolic blood pressure, smoking status, estimated glomerular filtration rate, cholesterol, or predicted annual risk of major vascular events; this finding was confirmed in a separate meta-analysis of 14 randomized trials from the same group.184 One study, the Collaborative Atorvastatin Diabetes Study (CARDS) trial, specifically assessed patients with type 2 diabetes mellitus, including 2838 patients in the United Kingdom and Ireland with a mean baseline LDL cholesterol of 117 mg/dL (3.0 mmol/L) randomized to atorvastatin 10 mg daily or placebo. A 37% reduction in the primary cardiovascular composite outcome (time to first occurrence of acute coronary heart disease event, coronary revascularization, or stroke) was observed for atorvastatin compared to placebo assigned groups. The Treating to New Targets (TNT) study examined whether lowering LDL cholesterol below the threshold recommended at the time (100 mg/dL, 2.59 mmol/L) would result in greater cardiovascular risk reduction.185 The study included 1501 patients with diabetes mellitus and coronary heart disease who were randomized to atorvastatin 10 mg versus 80 mg daily, lowering LDL cholesterol levels to a mean of 98.6 mg/dL (2.55 mmol/L) versus 77 mg/dL (1.99 mmol/L), respectively. There was a 25% reduction in major cardiovascular events (composite of coronary heart disease death, nonfatal nonprocedure-related myocardial infarction, resuscitated cardiac arrest and fatal or nonfatal stroke) after a median of 4.9 years of treatment. This study provides further evidence for more aggressive LDL-lowering to reduce ASCVD in diabetes mellitus.

Statins and Diabetes Mellitus
Although there are clear benefits of statins to reduce cardiovascular events and mortality in patients with or at risk for ASCVD,183,184 statins also modestly accelerate the development of diabetes mellitus in individuals with preexisting risk factors.186–189 In the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), which involved participants without diabetes mellitus but with LDL cholesterol levels <3.4 mmol/L (130 mg/dL) and high-sensitivity C-reactive protein concentrations of 2.0 mg/L or higher, the hazard ratio for newly diagnosed diabetes mellitus was increased 25% in the rosuvastatin group compared to the placebo group.186 Despite the increase in the risk of new-onset diabetes mellitus, the participants previously considered to be at low cardiovascular risk had clinically important cardiovascular event reductions over a median follow-up period of only 1.9 years, with a hazard rate 44% lower with rosuvastatin in comparison with placebo for the combined primary end point of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes. Almost two-thirds of participants had ≥1 major risk factor for developing diabetes mellitus: metabolic syndrome as defined by the 2005 American Heart Association/National Heart, Lung, and Blood Institute consensus criteria, impaired fasting glucose (as defined by fasting serum glucose of equal to or >100 and <126 mg/dL [5.55–7.00 mmol/L]), BMI 30 kg/m² or higher, or HbA₁c >6%.190 As expected, incident diabetes mellitus was 28% higher those with than without any major diabetes mellitus risk factor, and statins accelerated the average time to diagnosis of diabetes mellitus by 5.4 weeks. However, statin allocation reduced the risk for the primary end point both in participants with and without a major risk factor for diabetes mellitus, such that in patients with ≥1 risk factor for diabetes mellitus, in total 54 new cases of diabetes mellitus were diagnosed, whereas 93 first major cardiovascular events or deaths, or 134 total cardiovascular events or deaths were avoided.

Several meta-analyses have now been performed examining the risk of developing diabetes mellitus in statin-treated individuals, and relative risks are somewhat lower overall than that found in the index JUPITER trial.187–189 Diabetes mellitus relative risk was 13% higher with no heterogeneity across 5 trials (including HPS [Heart Protection Study],191 LIPID [Long-Term Intervention with Pravastatin in Ischemic Disease],192 ASCOT [Anglo-Scandinavian Cardiac Outcomes Trial],193 JUPITER,186 and CORONA [Controlled Rosuvastatin Multinational Trial in Heart Failure])194 with a total of 57593 patients, mean follow-up of 3.9 years, and 2082 incident cases of diabetes mellitus.187 Addition of WOSCOPS (West of Scotland Coronary Prevention Study)195 to the analysis introduced significant heterogeneity and attenuated risk, which no longer retained statistical significance as WOSCOPS reported a protective effect of pravastatin versus placebo on the incidence of diabetes mellitus. In a second meta-analysis, a 9% increase in risk for incident diabetes mellitus was found (odds ratio [OR], 1.09, 95% CI, 1.02–1.17), including 13 trials with 91 140 participants and development of diabetes mellitus in 4278 patients over a mean of 4 years.188 Investigators were contacted to obtain unpublished data regarding incident diabetes mellitus resulting in 7 additional trials (and both JUPITER and WOSCOPS) included as compared with the other meta-analysis. In this analysis little
heterogeneity was found across trials despite the inclusion of WOSCOPS, potentially attributable to different criteria used to diagnose diabetes mellitus. Statin-associated diabetes mellitus risk may be slightly higher in women.\textsuperscript{196} A meta-regression analysis showed the highest diabetes mellitus risk was associated with older age, but not baseline BMI or LDL cholesterol level.\textsuperscript{188} One extra case of diabetes mellitus resulted from treating 225 (95% CI, 150–852) patients with statins for 4 years, whereas 5.4 vascular events were prevented. In the larger context, given that statins are used by approximately 24 million Americans, the population-attributable risk of statin-associated diabetes mellitus is not small. However, considering the many treatments for diabetes mellitus and the importance of cardiovascular event reduction, providers should not avoid using statins when indicated solely because of concern for risk of diabetes mellitus.

Potential effects, if any, of statin-induced diabetes mellitus on the development of long-term microvascular complications remain unknown, but current epidemiological studies are reassuring. With recent lower lipid target goals and increasing use of statins, as well as improved screening, early detection, and multifactorial interventions, the age-adjusted percentage of adults with diabetes mellitus reporting visual impairment\textsuperscript{197} and the incidence of end-stage renal disease in adults with diabetes mellitus\textsuperscript{186} have decreased over the past few decades. Furthermore, the 10-year risk of myocardial infarction or stroke (\textasciitilde 25%) is markedly higher than that of blindness or renal failure (approximately 1%–2%) for patients with recent-onset diabetes mellitus.\textsuperscript{198} The risk of developing diabetes mellitus appears to be related to statin potency\textsuperscript{200} and dose.\textsuperscript{189} Cellular mechanisms underlying the increased incidence of diabetes mellitus remain incompletely understood. Genome-wide studies do not reveal associations between genes that regulate HMG-CoA reductase or LDL cholesterol metabolism and type 2 diabetes mellitus. Statins may interfere with \(\beta\)-cell insulin secretion either by decreasing Ca\(^{2+}\)-dependent insulin secretion or by interfering with isoprenylation of guanosine triphosphate–binding proteins.\textsuperscript{201} Statin inhibition of isoprenoid biosynthesis may lead to lower expression of insulin signaling proteins in adipocytes and to reduced glucose transporter expression or translocation.\textsuperscript{202} Fasting insulin levels may increase modestly, suggesting that insulin resistance may be increased, but euglycemic hyperinsulinemic clamp studies do not show consistent changes in insulin sensitivity.\textsuperscript{203} Other off-target effects may also be involved.

Overall, the risk of incident diabetes mellitus with statin therapy is present but largely outweighed by the actual cardiovascular benefits.\textsuperscript{204} Patients should be educated regarding the risk of incident diabetes mellitus with statins as with other risk–benefit of all therapies.\textsuperscript{152} Lifestyle modification should be encouraged to lower cardiovascular risk and that for developing diabetes mellitus.\textsuperscript{205} Patients on statins at higher risk for but without preexisting type 2 diabetes mellitus should undergo periodic screening for diabetes mellitus with fasting glucose and Hba\(_1c\), and if type 2 diabetes mellitus develops, standard of care and national guidelines should be used to manage diabetes mellitus.\textsuperscript{206,207}

**Non-Statin Lipid Lowering**

Although statins are effective in reducing ASCVD risk in diabetes mellitus, residual cardiovascular risk remains,\textsuperscript{185,191,208} and further lowering of lipids may be of value. Although most studies do not demonstrate other pharmacological class agents provide additional benefit, the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) supports use of a nonstatin LDL-lowering strategy to further lower cardiovascular risk.\textsuperscript{209} Vytorin is a combination of simvastatin and ezetimibe, which reduces intestinal cholesterol absorption. The primary composite cardiovascular end point of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization, or nonfatal stroke was 6% lower with ezetimibe in comparison with placebo administered with simvastatin. Ezetimibe lowered LDL cholesterol 24% despite the relatively low baseline concentrations, which was an unexpectedly potent effect on LDL cholesterol lowering. Twenty-seven percent of the study population had diabetes mellitus, and there was heterogeneity in response with a greater 14% cardiovascular benefit among those with diabetes mellitus. This trial supports the hypothesis that lower LDL cholesterol targets may be important to reduce residual ASCVD risk in patients with diabetes mellitus.

The question remains whether targeting the diabetic lipid abnormalities of high triglycerides, low HDL cholesterol, and small LDL cholesterol particle size will result in further benefit. Most trials examining effects of fibrates on cardiovascular risk were completed before statin therapy became widely instituted and included individuals with diabetes mellitus only as a subgroup. More recent trials include the lipid arms of Action to Control Cardiovascular Risk in Diabetes (ACCORD),\textsuperscript{210} which examined fenofibrate versus placebo on a background of simvastatin therapy, and the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial,\textsuperscript{211} involving fenofibrate monotherapy versus placebo. In ACCORD, all patients were randomized to intensive glycemic control (targeting an Hba\(_1c\) of 6.0%) or standard therapy (targeting Hba\(_1c\) of 7%–7.9%).\textsuperscript{211} A subset of patients were enrolled in the ACCORD Lipid trial and were randomized in a 2×2 factorial design to receive simvastatin plus fenofibrate or placebo. Inclusion in the ACCORD-Lipid substudy did not require high triglyceride and low HDL cholesterol levels, a group which might benefit most from fibrate therapy.\textsuperscript{210} Although there was no difference in the annual rate of the primary composite outcome of major adverse cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) for the fenofibrate in comparison with placebo group, prespecified subgroup analysis revealed 29% fewer events in those with baseline triglyceride \(\geq 204 \text{ mg/dL}(2.31 \text{ mmol/L})\) and HDL cholesterol 534 mg/dL (0.88 mmol/L). These results are consistent with the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study of 9975 individuals with type 2 diabetes mellitus not on statin therapy, randomized to micronized fenofibrate versus placebo for 5 years.\textsuperscript{192} No effect of fenofibrate was seen on the primary outcome of coronary events (coronary heart disease death or nonfatal myocardial infarction) in the entire cohort, although a 14% cardiovascular event reduction was observed.
in the subgroup with baseline low HDL cholesterol ($P=0.02$), and a similar trend was observed in those with baseline high triglyceride ($P=0.07$). Interpretation of the FIELD study is complicated because of higher rates of add-on statin use in the placebo-assigned treatment group, which might be expected to attenuate differences between groups. In total, 4 studies consistently demonstrate favorable effects of fibrates in the subgroup of patients with the specific lipid phenotype of high triglyceride and low HDL cholesterol,191,192,210,212 but one must be cautious in interpretation of subgroup analysis, especially when the primary outcome of the trial was not positive, and benefit of adding a fibrate to statin therapy for reducing risk of cardiovascular events in patients with type 2 diabetes mellitus remains unproven.213 Further studies are needed to determine whether persons with diabetes mellitus who have elevated triglyceride and low HDL cholesterol concentrations may realize a cardiovascular benefit with the addition of a fibrate.

In Atherosclerosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH),214 a study that evaluated addition of niacin to intensive statin therapy (with simvastatin plus ezetimibe if needed to maintain LDL of 40–80 mg/dL [1.04–2.07 mmol/L]) in patients with established cardiovascular disease and low HDL cholesterol (median baseline HDL cholesterol of 35 mg/dL [0.91 mmol/L], interquartile range, 31–39 mg/dL), approximately one-third of participants had diabetes mellitus. No difference in the primary composite end point was observed despite increased mean HDL cholesterol from 35 to 42 mg/dL (0.91–1.09 mmol/L), lowering triglycerides from 164 to 122 mg/dL (1.85 to 1.38 mmol/L), and lowering LDL cholesterol from 74 to 62 mg/dL (1.92 to 1.61 mmol/L). The trial was stopped 18 months early, after a mean follow-up period of 3 years, for lack of efficacy and an unexpected higher rate of ischemic stroke in the niacin group, although the overall rate was low, so it remains uncertain whether this was a true effect versus a chance occurrence. The trial must be interpreted with caution as the rate of the primary composite cardiovascular end point was lower than projected, consistent with recent trends, so the protocol was amended to change the primary end point of high-risk acute coronary syndrome to include hospitalization for acute coronary syndrome and symptom-driven coronary or cerebral revascularization. Furthermore, there have been no other studies before or since showing a causal link between niacin and stroke. Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) included >8000 patients with diabetes mellitus (32.3% of the study population) and compared extended-release niacin versus placebo on a background of statin therapy in high risk patients with previous vascular disease, but was likewise stopped early because of futility.215

Raising HDL cholesterol levels with the use of CETP inhibitors216,217 has not been demonstrated to reduce ASCVD risk, and torcetrapib unexpectedly increased ASCVD events, cardiovascular and noncardiovascular death.217 Although pharmacologically increasing HDL cholesterol concentrations has not been demonstrated to reduce ASCVD, it is possible that HDL cholesterol function, or cholesterol efflux capacity, is a more important determinant of cardiovascular risk.218 Given the data presented above, the opinions of the authors are that ezetimibe may represent a reasonable choice for additional cardiovascular risk reduction, especially in those with diabetes mellitus and acute coronary syndrome. Consideration can also be given to adding fibrate therapy for an individual with diabetes mellitus and residual hypertriglyceridemia with low HDL cholesterol levels once the patient is on goal statin therapy. The data do not support the specific use of niacin in diabetes mellitus, although it may be an alternative for those with true intolerance to statin therapy. These opinions are consistent with the most recent Standards of Medical Care for Diabetes by the American Diabetes Association (ADA),219 which cite the Level A evidence above to state that the addition of ezetimibe to moderate-intensity statin therapy may be considered for patients with a recent acute coronary syndrome with LDL cholesterol ≥50 mg/dL (1.3 mmol/L) or for those patients who cannot tolerate high intensity statin therapy. It was noted that combination therapy with a statin and fibrate has not been shown to improve ASCVD outcomes in the broad diabetes mellitus population and is generally not recommended, but therapy with statin and fenofibrate may be considered for men with both triglyceride level ≥204 mg/dL (2.3 mmol/L) and HDL cholesterol level ≤34 mg/dL (0.9 mmol/L). Lastly, combination therapy with statin and niacin was not generally recommended. Of note, the Scientific Statement on Prevention of Cardiovascular Disease in type 2 diabetes mellitus by the American Heart Association and American Diabetes Association (AHA/ADA) does not recommend addition of a fibrate to statin therapy.220

**LDL-Lowering With PCSK9 Inhibition**

The newest class of LDL-lowering medications consists of monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is present in hepatocytes, and binds to and targets the LDL receptor for degradation.221,222 PCSK9 inhibitors prevent the degradation of LDL receptors, allowing for increased removal of LDL cholesterol from the circulation. Individuals with loss-of-function PCSK9 mutations have lower LDL cholesterol levels and lower coronary heart disease incidence,223,224 whereas most cases of familial hypercholesterolemia result from gain-of-function mutations, elevated LDL cholesterol concentrations, and resulting early ASCVD.225,226 Statins upregulate PCSK9, which may be the reason that LDL cholesterol lowering with statins reaches a plateau.227 Alirocumab and evolocumab are 2 PCSK9 inhibitors recently approved by the Food and Drug Administration (FDA) based on their efficacy at lowering LDL cholesterol concentrations and initial safety based on relatively small trials, with additional clinical trials ongoing.

Alirocumab was approved by the FDA in July 2015 for use in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia or patients with clinical ASCVD who require additional lowering of LDL cholesterol. Doses of 75 to 150 mg subcutaneous administered every 2 weeks lowered LDL cholesterol concentrations by 36% to 59% in comparison with placebo in patients with hypercholesterolemia or at high cardiovascular risk as add-on therapy to background statins, on maximally-tolerated statins, or as monotherapy.228–234
longer-term studies ranged only from 24 to 78 weeks, but showed effects to lower LDL cholesterol are durable over this timespan. A post hoc analysis of the effect of alirocumab on cardiovascular outcomes was performed in the Long-term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients with Hypercholesterolemia Not Adequately Controlled with Their Lipid Modifying Therapy (ODYSEYY LONG TERM) trial and showed a 48% reduction in major adverse cardiovascular events (MACE; HR, 0.52; 95% CI, 0.31–0.90, nominal P=0.02), but this was based on adverse event reporting and these early trials were not designed as formal cardiovascular outcome trials. Thus definitive evidence of cardiovascular benefit awaits completion of a large ongoing trial in persons with a recent acute coronary syndrome event (NCT01663402), with planned enrollment of an estimated 18,600 patients and expected completion in late 2017.

The initial studies of alirocumab did not show an increased risk of diabetes mellitus but did suggest a smaller LDL cholesterol–lowering effect in diabetes mellitus. Larger populations will need to be studied to substantiate these effects. The most common side effects include itching, swelling, pain, or bruising at the injection site, nasopharyngitis, and flu. Allergic reactions such as hypersensitivity vasculitis have also been reported. A number of additional clinical trials are underway examining the safety and efficacy of alirocumab in statin-intolerant patients, patients at high cardiovascular risk on maximally-tolerated statins, as an add-on to statin therapy, and in patients with familial hypercholesterolemia.

Evolocumab is the second PCSK9 drug currently approved by the FDA to lower LDL cholesterol levels. Evolocumab was approved by the FDA in August 2015 for use in patients with heterozygous or homozygous familial hypercholesterolemia, or clinical ASCVD (eg, history of myocardial infarction or stroke), on diet therapy and maximally-tolerated statin therapy who require additional LDL cholesterol lowering. Evolocumab appears to have similar magnitude LDL cholesterol lowering effects as alirocumab, but these agents have not been compared in head-to-head investigations. In the evolocumab development program, cardiovascular outcomes were also examined as an exploratory end point in trials primarily designed to evaluate the LDL cholesterol–lowering effect of the drug. In a 48-week open-label study of evolocumab, patients were enrolled from either the phase-2 Open-Label Study of Long-Term Evaluation against LDL Cholesterol -1 (OSLER-1) or phase-3 (OSLER-2) trials. A dose of evolocumab 420 mg subcutaneous given monthly (in OSLER-1 and OSLER-2) or 140 mg every 2 weeks (OSLER-2) lowered LDL cholesterol by 61% at 12 weeks, an effect that was sustained at 58% at 48 weeks, with an absolute LDL cholesterol reduction of 70.5 mg/dL (1.83 mmol/L) to a mean LDL cholesterol level of 48 mg/dL (1.24 mmol/L). Likewise, durability of evolocumab lowering of LDL cholesterol was sustained for 52 weeks in the study of patients with familial hypercholesterolemia or mixed hyperlipidemia either alone or added on to low versus high intensity statin therapy. Additional beneficial effects on serum lipoproteins included decreased apoB, lipoprotein (a), triglycerides, and non-HDL cholesterol. Evolocumab has been shown to lower LDL cholesterol levels in patients with statin intolerance for 12 weeks as compared with statin plus ezetimibe, as an add-on to moderate or high intensity statin therapy for 12 weeks, and as monotherapy for 12 weeks. The prespecified exploratory outcome of adjudicated cardiovascular events (including death, coronary events of myocardial infarction, unstable angina requiring hospitalization, or coronary revascularization, and cerebrovascular events of stroke or transient ischemic attack, and heart failure requiring hospitalization) was reduced by 53% at 1 year (HR, 0.47; 95% CI, 0.28–0.78; P=0.003). The safety profile appeared to be acceptable at this early stage, although the duration of follow-up is short for chronic disease, and the sample size is small to detect less common potential safety signals. Briefly, injection-site reactions were reported in 4.3% of patients on evolocumab and led to discontinuation of the drug in 0.2%. New evolocumab-binding (neutralizing) antibodies were detected in 0.3% in the evolocumab group but in a surprising number of patients (also 0.3%) in the standard-therapy group. Antibody titers were transient in patients who underwent repeat testing, and no neutralizing antibodies against evolocumab were detected. The Further Cardiovascular Outcomes Research with PCSK9 inhibition in Subjects with Elevated Risk (FOURIER; NCT01764633) plans enrollment of 27,500 high-risk patients with cardiovascular disease on background statin therapy, with a primary MACE end point and is also expected to complete in late 2017. Additionally, 2 cardiovascular outcome trials are underway with bococizumab, a PCSK9 inhibitor that has not yet been approved by the FDA: SPIRE-1 (NCT01975376) and SPIRE-2 (NCT01975389).

Although PCSK9 inhibition has a potent and apparent durable effect to lower LDL cholesterol, the available clinical trial evidence regarding cardiovascular benefit is currently exploratory and preliminary, and definitive evidence is needed for reduction of cardiovascular outcomes. Furthermore, clinical trial data examining the effect of PCSK9 inhibitors on LDL-lowering and cardiovascular endpoints in patients with diabetes mellitus are needed, as the effects in this population remain uncertain.

Blood Pressure Control and Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy

The age-adjusted prevalence of hypertension is 57.3% in US adults with diabetes mellitus as compared with 28.6% in those without diabetes mellitus, with higher rates seen in older persons. Elevated blood pressure has unequivocally been shown to increase the risk of both micro- and macrovascular disease in diabetes mellitus, and blood pressure control reduces the risk of death and both micro- and macrovascular complications in type 2 diabetes mellitus. Initial trials investigated intensive versus moderate blood pressure control with secondary aims to also test particular drug classes. The Appropriate Blood Pressure Control in Diabetes (ABCD) trial was a prospective, randomized, controlled trial of intensive (diastolic blood pressure below 75 mm Hg) versus moderate (diastolic blood pressure between 80–89 mm Hg) antihypertensive therapy in 950 individuals with type 2 diabetes mellitus followed for 5 years. There was a further randomization to nisoldipine or enalapril. The trial was halted early because...
of marked lowering of cardiovascular complications (nonfatal myocardial infarction, all myocardial infarction, and myocardial infarction plus cardiovascular death) in patients randomized to enalapril. However, at the point of early termination of the randomization between the two drugs, the study had insufficient number of events to test any benefit of intensive blood pressure lowering on cardiovascular outcomes.

The benefits of angiotensin converting enzyme (ACE) inhibition observed in the ABCD trial were extended in the Heart Outcomes Prevention Evaluation (HOPE) study, which involved 3577 subjects with diabetes mellitus and a previous cardiovascular event (coronary artery disease, stroke, or peripheral artery disease) or ≥1 other cardiovascular risk factor (elevated total cholesterol, low HDL cholesterol, hypertension, known microalbuminuria, or current smoking) to either ramipril 10 mg daily or placebo, as well as vitamin E 400 IU versus placebo in a 2×2 factorial design.256 The trial was stopped 6 months early because of a 25% relative risk reduction in the combined primary outcome of myocardial infarction, stroke, or cardiovascular death in the group randomized to ramipril (95% CI 12–36, P=0.0004), and similar reductions in separate components of the primary outcome. The absolute risk reduction by ramipril was 4.5%, and this benefit remained significant even after adjustment for changes in systolic and diastolic blood pressure, suggesting that renin-angiotensin-aldosterone system (RAAS) inhibition may have greater benefits over and above blood pressure control in diabetes mellitus.

The impact of the RAAS inhibition approach was studied in the Losartan Intervention For Endpoint Reduction in Hypertension study (LIFE), which involved 1195 individuals with diabetes mellitus, hypertension, and signs of left ventricular hypertrophy to receive the angiotensin receptor blocker (ARB) losartan- or atenolol-based treatment.257 Both drug groups achieved similar blood pressure control, but the losartan-treated group had a 24% reduction in relative risk of the cardiovascular events (fatal and nonfatal myocardial infarction or stroke), after a mean follow-up of 4.7 years.

In contrast, in the Irbesartan Diabetic Nephropathy Trial (IDNT), a global multicenter trial of 1,715 adults with type 2 diabetes mellitus, diabetic nephropathy and hypertension, the use of irbesartan versus amlopidine or placebo in addition to conventional antihypertensive therapy did not confer a reduction in the composite cardiovascular end point.258 Other trials examining the use of ACE inhibition concomitant with ARBs have instead found increased risk for adverse events.259 Thus, there is not a uniform finding of unique cardiovascular benefit over and above blood pressure control of various strategies for RAAS inhibition in diabetes mellitus. However, consistent with the current AHA/ADA guidelines,260 RAAS blockade with an ACE inhibitor or ARB should be used first in the treatment of hypertension in diabetes mellitus. Because there is evidence that this combination can lead to more adverse events, the opinion of the authors agrees with current guidelines by the ADA that recommend avoiding combined therapy with ACE inhibition and ARBs simultaneously.261

The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial was a global, multicenter study conducted in 11,140 patients with type 2 diabetes mellitus randomized to fixed combination of the ACE inhibitor, perindopril, and the indoline diuretic, indapamide, or matching placebo in addition to current therapy.255 Patients were also randomized in a factorial design to standard versus intensive glucose-lowering therapy with a goal HbA1c of <6.5%. Approximately one-third of subjects had macrovascular disease at baseline. The initial trial had a mean follow-up of 4.3 years, and the mean achieved blood pressure was 139.3 mm Hg systolic and 78.7 mm Hg diastolic. The relative risk for the primary end point (a composite of major macrovascular and microvascular events) was reduced by 9% (HR, 0.91; 95% CI, 0.83–1.00; P=0.04), which reflected a 1.3% absolute risk reduction. The nearly 6-year long-term follow up of ADVANCE confirmed a sustained but attenuated benefit in reduction of all-cause and cardiovascular mortality.262

**Blood Pressure Goals**

The intensity of systolic blood pressure lowering was examined in the ACCORD-BP study, which included 4,733 participants with type 2 diabetes mellitus at high risk for cardiovascular events randomized to intensive blood pressure lowering therapy targeting a systolic blood pressure below 120 mm Hg, or standard therapy targeting a systolic blood pressure below 140 mm Hg.257 The mean achieved systolic blood pressure was 119.3 mm Hg in the intensive group and 133.5 mm Hg in the standard group. There was no statistical difference between groups in the primary composite outcome of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes, but there was a trend toward benefit after a mean follow-up of 4.7 years. However, there were more serious adverse events in the intensive in comparison with the standard therapy group (3.3% versus 1.3% of events attributed to blood pressure medications, P<0.001) including hypotension, bradycardia or arrhythmia, and hyperkalemia. Importantly, the mean estimated glomerular filtration rate was lower, and the serum creatinine was higher in the intensive group despite a lower prevalence of macroalbuminuria in the intensive group.

In contrast, results of the Systolic Blood Pressure Intervention Trial (SPRINT) support the benefits of intensive blood pressure control in the broad hypertensive population. Unfortunately this trial excluded patients with diabetes mellitus and thus the findings cannot be directly extrapolated to persons with diabetes mellitus.263 The trial does provide evidence supporting a much lower blood pressure goal than is represented in current guidelines and highlights an area of potential controversy. The study involved 9361 participants with systolic blood pressure between 130 to 180 mm Hg and an increased risk of cardiovascular events. Patients were randomized (but not fully blinded) to a systolic blood pressure target below 140 mm Hg (standard treatment) or below 120 mm Hg (intensive treatment). The antihypertensive regimen titration algorithm was similar to that used in the ACCORD-BP trial. The primary composite cardiovascular outcome (myocardial infarction, other acute coronary syndrome, stroke, heart failure, or death from cardiovascular causes) was significantly reduced with a hazard ratio of 0.75 with intensive treatment (95% CI, 0.64–0.89; P<0.001) with participants followed over a mean of 3.26 years. In general, the SPRINT cohort was
older than ACCORD (28% of subjects were age 75 or older, mean age 68 years compared with 62 years in ACCORD-BP), and included individuals with chronic kidney disease. There was more syncope and hypotension but not more falls in the intensive treatment group, and there was a higher rate of acute kidney injury and acute renal failure in the intensive treatment group. At this time, it is unclear why there is greater benefit in the primary outcome in SPRINT versus only a trend for benefit in the ACCORD-BP but in fact the point estimates for the primary outcome and components of the primary showed similar trends in both trials. Outcomes data for SPRINT versus ACCORD are compared in Figure 3.259

Several meta-analyses provide insight into the collective clinical experience of lowering blood pressure in diabetes mellitus. One such meta-analysis identified 40 trials with 100,354 participants performed either exclusively in type 2 diabetes mellitus or included trial population subgroups with diabetes mellitus.260 In diabetes mellitus every 10 mm Hg of systolic blood pressure lowering has an associated 13% reduction in all-cause mortality, 11% reduction in cardiovascular events, and 27% reduction in stroke events. This meta-analysis also reveals substantial benefit in lowering blood pressure on reducing microvascular events. Importantly, antihypertensive drug class does not affect the overall results; rather, it is the blood pressure lowering per se that confers clinical benefit. However, there are differences between particular drugs and individual cardiovascular endpoints. For example, diuretics are associated with a 17% lower relative risk for heart failure (mainly driven by ALLHAT), and ARBs are associated with a lower relative risk of heart failure and mortality (mainly driven by LIFE in which ARBs were compared with β-blockers). In contrast, calcium channel blockers are associated with a higher relative risk of heart failure but a lower risk of stroke, whereas β-blockers appeared to be associated with a higher relative risk of stroke. What is important in putting individual antihypertensive drugs in perspective is that blood pressure lowering by any drug class is associated with cardiovascular benefit in diabetes mellitus, but in individual patients, tailoring drug selection to address a particular cardiovascular concern (such as risk of heart failure versus risk of stroke) may be necessary.

In all, only 3 randomized controlled trials have examined the effect of standard versus more intensive blood pressure lowering in individuals with diabetes mellitus.249,257,261–263 Whereas the ACCORD-BP trial257 focused on systolic blood pressure, the others targeted control of diastolic blood pressure. A recent meta-analysis including these 3 trials of a total of 7312 adult participants with type 2 diabetes mellitus and hypertension followed for 2 to 5 years.264 Intensive reduction of systolic blood pressure to 130 mm Hg or lower or diastolic blood pressure to 80 mm Hg or lower was associated with a 35% decrease in risk for stroke (RR, 0.65; 95% CI, 0.48–0.86) and a trend for reduced mortality (RR, 0.76; 95% CI, 0.55–1.05) as compared with a standard systolic blood pressure target of 140 to 160 mm Hg and diastolic blood pressure target of 85 to 100 mm Hg. However, these results are somewhat inconclusive because of the very different trial designs and blood pressure targets. The total sample size and number of events may not have been sufficient to detect significant benefit for all cardiovascular end points. On a cautionary note,

Figure 3. Cardiovascular outcomes in 2 recent blood pressure–lowering trials in patients with and without baseline diabetes mellitus. Outcomes data for blood pressure–lowering trials in a high-risk population without diabetes mellitus: SPRINT (Systolic Blood Pressure Intervention Trial, n=9361) and in a high-risk population with diabetes mellitus: ACCORD (Action to Control Cardiovascular Risk in Diabetes, n=4733). SPRINT was conducted in patients without diabetes and ACCORD in patients with diabetes mellitus. Although reduction in individual outcomes did not reach statistical significance in ACCORD except for stroke, trends toward benefit were similar, and combining ACCORD with SPRINT demonstrated a reduction in the primary outcome and in individual components with intensive treatment. Reprinted from Perkovic et al with permission of the publisher. Copyright ©2015, Massachusetts Medical Society.
ACCORD-BP demonstrated a significant increase in serious adverse events with intensive blood pressure lowering, as described above.

The 2016 Standards of Medical Care by the ADA,219 the 2015 AHA/ADA Scientific Statement Update,220 and the most recent American Heart Association guidelines for cardiovascular risk reduction132 recommend a blood pressure goal of <140 mm Hg for systolic blood pressure and <90 mm Hg for diastolic blood pressure. Initial antihypertensive therapy should include an ACE inhibitor, or ARB if the ACE inhibitor is not tolerated, for renal protection. If the blood pressure is not at target, the next choice could include a thiazide diuretic or calcium channel blocker. In the context of the recently-published SPRINT results in patients without diabetes mellitus, it is the opinion of the authors that it would be reasonable to also consider targeting blood pressure <120/80 in individuals with diabetes mellitus, especially in the presence of renal disease (elevated urine albumin excretion or chronic kidney disease) or increased risk for stroke, while exercising caution in patients with symptoms of hypotension or requiring multiple agents to achieve this target (Table 1).

**Antithrombotic Medications**

Platelet activation and atherothrombosis play key roles in acute coronary syndromes, cerebrovascular events, and the formation and progression of atherosclerotic plaques.265 The benefits of aspirin in patients with acute or previous vascular disease were first assessed in clinical trials published >20 years ago involving >100,000 patients in placebo-controlled trials.267 Meta-analyses of these trials clearly established benefit of aspirin for secondary prevention in patients at high risk attributable to established cardiovascular disease,268 defined as patients with an acute or previous history of myocardial infarction, a past history of stroke or transient ischemic attack, and patients with stable or unstable angina, vascular surgery, angioplasty, and peripheral artery disease (but not just multiple risk factors). In these patients aspirin was associated with a 27% odds reduction in MACE events. However, in low-risk patients (primary prevention) aspirin had a nonsignificant 10% reduction in MACE events.

In early meta-analyses from 1994, diabetes mellitus was included as a high-risk group that demonstrated cardiovascular risk reduction with antiplatelet therapy with regimens consisting predominantly of ticlopidine, dipyridamole, and sulphinpyrazone.267 In these early trials in diabetes mellitus, only 2 of 10 studies evaluated aspirin (with or without dipyridamole). In those 2 studies of aspirin in diabetes mellitus, there were 399 cardiovascular events on the aspirin regimen and 414 on control. In 2002, an update from the antiplatelet trialists’ also included diabetes mellitus as a high-risk subgroup.268 This update included 4961 patients with diabetes mellitus from 9 trials and demonstrated that antiplatelet therapy was associated with only a 7% proportional reduction in serious vascular events in those with diabetes mellitus, as compared with a 25% reduction overall, but wider confidence limits do not exclude benefit for this group. Thus antiplatelet therapy in diabetes mellitus, particularly with the use of aspirin, may be less effective at cardiovascular risk prevention than in patients without diabetes mellitus. It should also be noted that these trials were performed at a time when intensive management of LDL cholesterol and blood pressure were not well established.

Therefore, although the benefit of aspirin in secondary prevention is established, benefit of aspirin in primary prevention of ASCVD in individuals with diabetes mellitus is less clear.219,270 There are 3 recent published clinical trials of aspirin therapy for primary prevention of cardiovascular disease in diabetes mellitus: the Early Treatment Diabetic Retinopathy Study (ETDRS),271 Prevention of Progression of Arterial Disease and Diabetes (POPADAD),272 and Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD).273 ETDRS compared aspirin 650 mg daily versus placebo in 3711 patients with diabetes mellitus (type 1 or type 2 diabetes mellitus) and retinopathy, and showed patients receiving aspirin had a numeric decrease in the risk of nonfatal or fatal myocardial infarction; however, the confidence interval crossed 1 (RR, 0.85; 95% CI, 0.73–1.00). POPADAD was a multicenter study of 1276 adults with type 1 or type 2 diabetes mellitus with subclinical cardiovascular disease defined as a reduced ankle-brachial index in the lower extremity (Figure 4). This study used a 2x2 factorial design with aspirin 100 mg daily or an antioxidant capsule. No effect of aspirin (or antioxidant capsule) on the composite primary cardiovascular end points (HR, 0.98) was found after a median follow-up period of 6.7 years. JPAD included 2539 patients with type 2 diabetes mellitus without known ASCVD in a multicenter study in Japan, randomized to receive 81 to 100 mg aspirin daily or no aspirin (placebos were not allowed in physician-directed studies at that time) and followed for 4.37 years (Figure 4). The lower rate of the primary end point on aspirin treatment did not reach statistical significance (5.4% of subjects in the aspirin group reached the primary end point whereas 6.7% of subjects did so in the nonaspirin group, P=0.16). Importantly, the primary outcome event rate was quite low, and the investigators did not feel that their study was powered to detect a difference between treatment groups. Subsequently, 2 subgroup analyses of JPAD have been published which need to be interpreted with caution give the overall negative trial. These subgroups had even fewer events but suggested possible benefit of aspirin therapy to reduce cerebrovascular events in patients with type 2 diabetes mellitus and poorly controlled blood pressure274 or high C-reactive protein.275 An important study limitation is that the initial trial did not reach statistical significance; hence as subgroup analyses of a negative trial, these present intriguing hypothesis-generating conclusions which must be considered with caution in clinical practice. Several meta-analyses examining the effect of aspirin for primary prevention of ASCVD in diabetes mellitus have also been published276–278 as well as a meta-analysis performed in the general population.279 Intriguingly, early data suggest that twice daily dosing may increase the beneficial effect,279,280 and support further study. However, the mechanism for potential greater benefit with twice daily aspirin dosing remains unclear as aspirin covalently modifies cyclooxygenase-1, leading to inhibition of platelet aggregation. As platelets are anucleated cells they cannot synthesize new cyclooxygenase-1, so antiplatelet
Table 1. Suggested Treatment Prioritization to Reduce ASCVD Risk in Type 2 Diabetes Mellitus

<table>
<thead>
<tr>
<th>Vascular territory</th>
<th>Primary Prevention</th>
<th>Secondary Prevention (Coronary/Carotid Disease)†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Macrovascular and microvascular</td>
<td>• Moderate intensity statin</td>
<td>• High intensity statin</td>
</tr>
<tr>
<td></td>
<td>• Guidelines recommend BP &lt;140/90 mm Hg but consider targeting &lt;120/80 mm Hg if tolerated, especially in renal disease or increased stroke risk.¶</td>
<td>• Guidelines recommend BP &lt;140/90 mm Hg but consider targeting &lt;120/80 mm Hg if tolerated, especially in renal disease or increased stroke risk.¶</td>
</tr>
<tr>
<td></td>
<td>• Use caution with multiple agents to avoid hypotension</td>
<td>• Use caution with multiple agents to avoid hypotension</td>
</tr>
<tr>
<td></td>
<td>• Low dose aspirin or no aspirin‡</td>
<td>• Low-dose aspirin or no aspirin‡</td>
</tr>
<tr>
<td></td>
<td>• Early glycemic control may reduce later ASCVD risk#</td>
<td>• Low-dose aspirin</td>
</tr>
<tr>
<td>Microvascular</td>
<td>• HbA1c ≤ 6.5% if able to achieve with minimal hypoglycemia</td>
<td>• HbA1c ≤ 7.0% if able to achieve with minimal hypoglycemia</td>
</tr>
<tr>
<td></td>
<td>• HbA1c ≤ 7.0% if multiple diabetes mellitus drugs are tolerated and polypharmacy does not diminish intensity of CV risk management; HbA1c ≤ 7.5% if not tolerated</td>
<td>• HbA1c ≤ 7.0% if multiple diabetes mellitus drugs are tolerated and polypharmacy does not diminish intensity of CV risk management; HbA1c ≤ 7.5% if not tolerated</td>
</tr>
</tbody>
</table>

Author-recommended approach to cardiovascular risk reduction in type 2 diabetes mellitus: recommendations for aggressive blood pressure control and limitation of aspirin to patients with established coronary artery disease do not necessarily agree with guideline recommendations but do reflect the authors’ assessment of the current literature. ASCVD indicates atherosclerotic cardiovascular disease; BP, blood pressure; CV, cardiovascular; CVD, cardiovascular disease; HbA1c, hemoglobin A1c.

*Diabetes mellitus per se confers an increased risk of ASCVD, so the vast majority of diabetes mellitus patients without ASCVD fall into the moderate or high ASCVD risk category; treatment should be individualized and a few patients may fall into a lower risk category, but all patients should undergo lifestyle intervention. Special caution should be used in the elderly.

†Coronary or carotid disease refers to a clinical history of an acute ischemic event (acute coronary syndrome or ischemic stroke) or coronary revascularization.

‡Randomized trials of lifestyle interventions of diet, exercise and weight loss in diabetes mellitus have not shown a reduction in CV events.265 However, lifestyle modification and weight loss help improve CV risk factors and result in other positive health outcomes.

§Additional lip-losing therapies could include fibrates in persons with diabetes mellitus and elevated triglyceride and low HDL cholesterol levels.

¶The AHA/ADA Guidelines12,279 recommend BP <140/90 mm Hg but consider targeting <120/80 mm Hg if tolerated,264 especially in renal disease or increased stroke risk. Cardiovascular disease includes elevated urine albumin excretion or chronic kidney disease.

‖The AHA/ADA Guidelines12,279 recommend low-dose aspirin for those with 10-year CVD risk of >10% without increased risk of bleeding as well as those at intermediate risk (10-year CVD risk 5% to 10%) but the evidence is Level B and C, and data to support this are controversial.

¶A period of good glycemic control (HbA1c, 7% vs 7.9%) in patients with newly-diagnosed type 2 diabetes mellitus led to a reduction in MI and all-cause mortality after 20 years.

Effects extend over the duration of the platelet lifespan. Taken together, the recent evidence for aspirin in diabetes mellitus without baseline clinical cardiovascular disease has largely been neutral (Figure 4), and recommendations for aspirin use must be tempered by increased risk for bleeding.

The 2016 ADA Standards of Medical Care for Diabetes recommendations regarding aspirin therapy are consistent with the AHA and American College of Cardiology Foundation statement on aspirin for primary prevention of cardiovascular events in people with diabetes mellitus, suggesting that low-dose aspirin should be considered in patients with increased CV risk (10-year risk >10%) and for those at intermediate risk, but not for those at low risk for ASCVD (10-year risk <5%).219,278 Unfortunately, there is no direct clinical trial evidence to support these risk-based treatment recommendations, creating an area of controversy in primary prevention for patients with diabetes mellitus. This is in contrast to the clear benefit as outlined in the guidelines for secondary prevention in diabetes mellitus, which recommend aspirin therapy (75–162 mg daily) in individuals with diabetes mellitus and a history of ASCVD. Additionally, dual antiplatelet therapy is reasonable up to 1 year after an acute coronary syndrome. Based on the Dual Antiplatelet Therapy study, in which almost one-third of patients had diabetes mellitus, extending dual antiplatelet therapy beyond 1 year after implantation of a drug-eluting stent in patients who have tolerated dual antiplatelet therapy without recurrent ischemic events or bleeding may be considered to reduce major adverse cardiac and cerebrovascular events and stent thrombosis.

Lifestyle

An intensive program including counseling about medical nutrition therapy, physical activity, and behavior change, with ongoing support and frequent follow-up are needed for lifestyle management of weight, cardiovascular risk factors,
and glyceremia itself in diabetes mellitus.  

Weight loss, a healthy eating pattern, and increasing physical activity are also effective for reducing cardiovascular risk factors in individuals without diabetes mellitus, and are effective for prevention of diabetes mellitus. Lifestyle interventions should be recommended in all patients with diabetes mellitus, patients at risk for ASCVD, and patients with known ASCVD.

The Look AHEAD trial is the seminal study of lifestyle intervention in type 2 diabetes mellitus treatment, conducted as a multi-center, US-only trial of 5145 obese or overweight patients with type 2 diabetes mellitus randomized to receive intensive lifestyle intervention consisting of frequent visits, calorie restriction, and physical activity versus a control group who received only standard diabetes mellitus education and support. The primary end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for angina, with a maximum follow-up planned for 13.5 years. Despite greater weight loss, reduction in HbA1c, and improvements in fitness and cardiovascular risk factors in the intervention group, there was no difference in the primary outcome between treatment arms (HR, 0.95; 95% CI, 0.83–1.09; P=0.51), resulting in early trial termination for futility at a median follow-up of 9.6 years. The narrow 95% CI for the primary outcome was consistent with the conclusion that the absence of between-group differences was not attributable to lack of a sufficient number of primary end point events.

More than half of adults in the US with diabetes mellitus are obese, and >75% are overweight. One of the cornerstones for lifestyle management of ASCVD consists of weight loss for individuals who are obese or overweight. Weight loss results in increased HDL cholesterol levels, decreased triglycerides, and decreased blood pressure. A modest degree of weight loss (5% to 7% of body weight) is recommended with similar clinical recommendations for individuals with or without diabetes mellitus. Another parallel goal is to prevent weight gain, and certain glucose-lowering medications are more likely to result in weight gain (insulin, sulfonylureas, and thiazolidinediones), whereas others are either weight neutral (dipeptidyl peptidase 4 [DPP4] inhibitors, or gliptins), and some result in weight loss (metformin, glucagon-like peptide [GLP]-1 receptor agonists and sodium-glucose cotransporter [SGLT2] inhibitors, or gliflozins). Interestingly, the use of insulin does not preclude weight loss, and short- and long-term weight loss can occur with adherence to treatments. The most effective strategies for weight loss in diabetes mellitus include a Mediterranean diet and an intensive program combining diet and physical activity. Participants in the intensive lifestyle arm of the Look AHEAD trial maintained a weight loss of 6% of body weight at 10 years as compared with 3.5% in the standard lifestyle group. Strategies that were associated with decreased BMI in the Look AHEAD study included self-weighing on a weekly basis, eating breakfast regularly, and reducing the intake of fast foods, increasing physical activity, decreasing portion sizes, and meal replacements.

Recommendations for healthy eating should be individually tailored according to caloric requirements, personal and cultural food preferences, type of diabetes mellitus, prescribed medications, and comorbid medical conditions. General recommendations include reducing the intake of saturated fat (to 5% to 6% of total calories), eliminating transfat, lowering sodium intake (to <2300 mg/d or even lower, to <1500 mg/d), and increasing intake of dietary fiber. A Mediterranean-style diet high in monounsaturated fatty acids is a recommended alternative to consuming a higher carbohydrate low-fat diet to control glyceremia and cardiovascular risk factors. Although there have been many clinical trials examining low versus high carbohydrate diets in patients with insulin resistance or diabetes mellitus, the long-term cardiovascular effects of diets low in carbohydrates have not been examined adequately, and an optimal combination of macronutrients cannot be recommended for type 2 diabetes mellitus to prevent ASCVD. To help control lipids and blood pressure, a dietary pattern that focuses on the intake of vegetables, moderate amounts of fruit and whole grains, poultry, fish, low-fat dairy, legumes, non-tropical vegetable oils and nuts, and limits the intake of sweets, sugar-sweetened beverages and red meats is recommended. The Dietary Approaches to Stop Hypertension (DASH) diet, the ADA recommendations for medical nutrition therapy, and the American Heart Association/American College of Cardiology lifestyle management guidelines can all be used to guide dietary recommendations. Alcohol intake in patients with diabetes mellitus can increase the risk for delayed hypoglycemia and blunt...
symptom recognition, so patient education regarding management strategies is needed.

Physical inactivity is associated with increased risk of mortality. A number of epidemiological studies show regular physical activity reduces cardiovascular and total mortality in patients with diabetes mellitus or prediabetes. Moderate or high levels of physical activity were associated with a reduced risk of total and cardiovascular mortality, independent of BMI, blood pressure, total cholesterol, and smoking, in a cohort of 3708 individuals with type 2 diabetes mellitus in Finland followed prospectively for a mean of 18.7 years. Even being physically active only occasionally (less than once a week) reduces the risk of all-cause mortality by 28%, whereas exercising once a week confers a 40% lower risk of mortality compared with being completely sedentary. However, individuals with type 2 diabetes mellitus may have more barriers to exercise than people without diabetes mellitus that limit successful implementation of a physical activity prescription, including presence of comorbidities, risk of hypoglycemia related to glucose-lowering medications, presence of microvascular complications such as visual impairment, peripheral and autonomic neuropathy, and even decreased functional exercise capacity, which can increase the discomfort associated with initiating a bout of physical activity. It should also be noted that no clinical trials have demonstrated that physical activity per se reduces cardiovascular events in diabetes mellitus. Despite the fact that the Look AHEAD study did not demonstrate a reduction in cardiovascular outcomes for intensive lifestyle intervention in comparison with standard advice, there were a number of other benefits including increased physical fitness, reduction in diabetic renal disease, and remission of diabetes mellitus, which have positive impacts on cardiovascular risk, and reduction of glucose-lowering medications and depression, which both have direct impact on quality of life. Every attempt must be made to promote and reinforce lifestyle management recommendations and to refer individuals with diabetes mellitus to specialists if hypoglycemia or fear of hypoglycemia present a barrier to implementing lifestyle interventions.

**Glycemic Control**

Although patients with type 2 diabetes mellitus may be able to achieve glycemic targets without use of glucose-lowering medications, this is often possible only soon after diagnosis when the degree of hyperglycemia is mild to moderate or significant modifiable aspects of lifestyle are contributing to the patient’s disordered glucose metabolism (eg, excess weight, a dietary pattern high in excess calories and refined carbohydrates and low in viscous fiber, little to no physical activity). Diabetes mellitus is a progressive, chronic condition, and although there are multiple pathophysiologic mechanisms contributing to hyperglycemia in diabetes mellitus, progressive β-cell failure is a key aspect of the natural history of type 2 diabetes mellitus with gradually worsening hyperglycemia and rising HbA1c. Eighty-five percent of individuals with established diabetes mellitus take glucose-lowering medications, making up 17.7 million people in the US. Because ASCVD in the form of myocardial infarction and stroke accounts for up to 80% of mortality in type 2 diabetes mellitus, medications taken to manage hyperglycemia must not adversely impact cardiovascular risk factors or increase ASCVD, and ideally would ameliorate or reverse atherosclerosis and lower cardiovascular risk. However, many of the medications available to treat hyperglycemia in diabetes mellitus have no effect on cardiovascular risk or may have a theoretical concern for exacerbating cardiovascular risk factors or cardiovascular disease itself. Although lowering glucose concentrations will ameliorate immediate symptoms of hyperglycemia (polyuria, polydipsia, and weight loss) and longer term microvascular disease, there is less evidence for targeting HbA1c to lower cardiovascular risk.

Intensive glycemic control reduces relative risk of nonfatal myocardial infarction and coronary heart disease events by about 15%, although there is no effect of intensive glycemic control on all-cause mortality in meta-analysis of the multiple randomized clinical trials targeting different intensity of glycemic control. Most studies are of relatively short duration, and long-term follow-up of both the Diabetes Control and Complications Trial (DCCT) and United Kingdom Prospective Diabetes Study (UKPDS) show reduced risk for cardiovascular events emerge over time in those with currently diagnosed type 1 or type 2 diabetes mellitus, respectively, who were previously randomized to intensive glycemic control. However, these effects take years to manifest and few studies extend observations over the extended timeframe which may be necessary to realize benefit of glucose lowering per se. Therefore reasonable glycemic control, targeting HbA1c below 7% may be appropriate for those with ASCVD or multiple risk factors but long life expectancy, whereas higher targets, above 7% but below levels associated with signs and symptoms of hyperglycemia, are appropriate for those with more limited life expectancy or in whom lower targets cannot be achieved safely.

The UKPDS follow-up study provides the strongest evidence to date for glucose control and reduction in cardiovascular events and mortality in type 2 diabetes mellitus. UKPDS enrolled patients with newly-diagnosed type 2 diabetes mellitus who were randomized to intensive versus standard glycemic control and followed for 10 years, with prolonged follow-up study over an additional 10 years of observation without further intervention, during which time participants returned to their primary care physicians for clinical care. The initial separation of HbA1c of 0.9% (mean HbA1c 7.0% in the intensive group and 7.9% in the conventional treatment group) was lost early in the follow-up observation study, during which the average HbA1c in the 2 groups converged. Although not seen initially over the first 10 years when glycemic differences were achieved, a 15% relative risk reductions for myocardial infarction and 13% risk reductions for death from any cause emerged over time, despite loss of between group differences in HbA1c over the first year of prolonged observation. As similar latent benefits have been seen in type 1 diabetes mellitus in the context of the DCCT, a “legacy effect” or “metabolic memory” has been postulated, with persistence of benefits of initial good glycemic control (and conversely, persistent adverse effects of poor glycemic control). It has been proposed that the long period of time required to see...
an effect of glycemic control on cardiovascular risk may be partially explained by improved adherence of all study participants to other aspects of cardiovascular risk factor reduction, such as use of statins and ACE inhibitor diluting effects of glycemic control per se on cardiovascular endpoints.\textsuperscript{41} Reductions in cardiovascular risk have not been observed in subsequent large, randomized, controlled trials of intensive glucose-lowering in type 2 diabetes mellitus over shorter duration in patients with more advanced cardiovascular disease. It remains uncertain whether absence of benefit is attributable to inclusion of patients with advanced disease beyond a period of reversibility, short trial duration for effect to manifest, safety of glucose lowering with current available interventions, or absence of effect of glucose lowering per se. Studies have not revealed improvement in primary cardiovascular endpoints with lowering of HbA\textsubscript{1c} below 6.5\% to 7\%\textsuperscript{333–335} and even raise concern about increasing cardiovascular risk, as seen in ACCORD.\textsuperscript{333} Meta-analyses of trials that include ACCORD, ADVANCE, and the Veterans Affairs Diabetes Trial (VADT) support glucose-lowering as beneficial for reducing composite cardiovascular end points and nonfatal myocardial infarction, but there was no effect on total mortality which warrants further investigation.\textsuperscript{329,336–338} Evaluating these potential benefits of intensive glycemic control in low-risk diabetes mellitus is challenging because of low event rates needed to achieve adequate statistical power. It should be noted that ACCORD was designed to define the most effective combinatorial treatment of risk factors in type 2 diabetes mellitus (glycemia, blood pressure, lipids) to maximally reduce cardiovascular risk.\textsuperscript{339} The trial was stopped prematurely because of the unexpected finding of increased all-cause mortality (primarily cardiovascular; HR, 1.21; 95\% CI, 1.02–1.44), although without difference in the rate of the primary outcome (a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes; \(P=0.13\)) and fewer nonfatal myocardial infarctions. The increase in cardiovascular death was driven in part by congestive heart failure, in the setting of fewer nonfatal myocardial infarctions in the intensive treatment group. Neither ADVANCE nor VADT demonstrated an increased mortality or composite cardiovascular risk with intensive glycemic control as defined by HbA\textsubscript{1c} <7\%.\textsuperscript{334,335}

Several explanations may account for discrepant findings in UKPDS and ACCORD, ADVANCE, and VADT.\textsuperscript{24,247} Patients in UKPDS had newly-diagnosed diabetes mellitus, whereas patients with type 2 diabetes mellitus enrolled in the other 3 trials had established coronary artery or macrovascular disease at baseline (32\% to 40\%), which was an intentional aspect of trial design in ACCORD, ADVANCE, and VADT. Average achieved HbA\textsubscript{1c} ranged from 6.4 to 6.9\% in the intensive treatment groups in ACCORD, ADVANCE, and VADT, but was higher in UKPDS. As anticipated, there were fewer cardiovascular events in ACCORD subjects without prior cardiovascular disease or with baseline HbA\textsubscript{1c} <8\%. However, only the subset of participants with baseline HbA\textsubscript{1c} >8.5\% in the intensive treatment group was found to be at higher risk for mortality. Besides higher baseline HbA\textsubscript{1c}, increased mortality was associated with history of neuropathy and higher HbA\textsubscript{1c} on treatment, with higher mortality occurring in the subset of patients randomized to intensive control but unable to achieve target glycemia.\textsuperscript{340–343} A higher average on-treatment HbA\textsubscript{1c} was also a strong predictor of mortality regardless of treatment group.\textsuperscript{43} There was a linear increase in risk for mortality with increasing HbA\textsubscript{1c} across the range of 6\% to 9\% in the intensive-treatment group, although there was a U-shaped relationship in the standard-treatment group, with lowest hazard rates of all-cause mortality in the intensive control group achieving lowest glycemic targets but at HbA\textsubscript{1c} of 7\% to 8\% for standard-of-care,\textsuperscript{343} suggesting factors associated with inability to achieve glycemic targets influence mortality, including diverse factors such as more severe underlying disease, inability to adhere to lifestyle or pharmacological regimens, or drug interactions with use of polypharmacy in attempt to achieve goals. Although individuals with severe hypoglycemia in ADVANCE had a higher risk for death, the higher incidence of severe hypoglycemia in the intensive treatment group was not associated with higher risk for cardiovascular endpoints.\textsuperscript{334} Furthermore, although there were more instances of severe hypoglycemia in the intensive treatment group in ACCORD, lower rather than higher mortality was observed for those with severe hypoglycemia in this group.\textsuperscript{344}

The VADT follow-up study\textsuperscript{345} demonstrated that an expanded MACE end point was reduced significantly in the intensive treatment group; however, cardiovascular death was not, tempering enthusiasm for the results and consistent with previous meta-analyses showing that intensive glycemic control reduces relative risk of nonfatal myocardial infarction and coronary heart disease events but without an effect on mortality. Subgroup analysis suggests that persons without macrovascular disease at baseline may benefit the most, but these are not necessarily the patients who were enrolled in many of the CV outcome trials.

**Insulin-Sparing Versus Insulin-Provisional Strategies**

Epidemiological studies demonstrate a higher prevalence of cardiovascular disease in patients treated with insulin.\textsuperscript{326,346} Although this has raised concern about the safety of insulin, this concern has not been born out in multiple studies\textsuperscript{104,347} and may be the result of indication bias, because insulin tends to be used more in patients with more severe diabetes mellitus of longer duration, which coincides with factors that increase cardiovascular risk. BARI-2D examined insulin provisional versus insulin sparing (sensitization) therapies in 2368 patients with type 2 diabetes mellitus and heart disease undergoing prompt revascularization with intensive medical therapy as compared with intensive medical therapy alone.\textsuperscript{104} There was no difference in survival or freedom from major adverse cardiovascular events in groups randomized to receive insulin or a sulfonylurea versus metformin or a thiazolidinedione. Likewise, insulin glargine had a neutral effect on cardiovascular outcomes when used to target normal fasting plasma glucose levels for more than 6 years, in patients with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes mellitus.\textsuperscript{347} Furthermore, randomized, controlled trials utilizing insulin therapy as part of the glycemic lowering strategy have not shown an increase
in cardiovascular risk with insulin. However, it is plausible that there could be differences in potential cardiovascular risks for different forms of insulin; the most recent example was a delay in approval of insulin degludec by the Food and Drug Administration because of initial concerns about a signal for increased risk of major adverse cardiovascular events, although the upper limit of risk if present must be small as the FDA has approved degludec based on interim data while the definitive cardiovascular outcome trial is ongoing (NCT01959529).

Hemoglobin A1c as a Surrogate End Point
When the Diabetes Control and Complications Trial (DCCT) showed substantial decreases in microvascular complications with intensive glycemic control in type 1 diabetes mellitus, and similar reductions in risk for development or progression of microvascular complications with intensive glycemic control were observed in type 2 diabetes mellitus. HbA1c as a measure of average glycemia over time became recognized as a surrogate end point intended to substitute for the clinical end point of microvascular disease. Importantly, an appropriate surrogate end point should be highly associated with the disease and disease severity such that a treatment effect on a surrogate biomarker should be directly correlated with clinical benefit, whereas lack of treatment on a surrogate end point should be associated with no clinical benefit. In DCCT, although differences in HbA1c between intensive and standard treatment groups explain virtually all of the differences in risk of retinopathy between groups, total glycemic exposure (HbA1c and duration of diabetes mellitus) accounts for only 11% of the variation in retinopathy risk in the complete cohort. Other factors, such as genetics, environment, and nonglycemic risk factors, including dyslipidemia and blood pressure, presumably account for the remaining 89% variability in risk of retinopathy complications in patients with diabetes mellitus independent of HbA1c. Therefore, HbA1c is only 1 indicator of risk for microvascular complications of diabetes mellitus, and whether HbA1c is a valid surrogate end point for macrovascular disease risk remains uncertain. Investigation into new risk markers that account for factors not captured by HbA1c that may impact risk of complications and risk prediction models including these new putative factors is needed.

Bariatric Surgery
Bariatric surgery induces substantial and sustained weight loss and remission or improvement in type 2 diabetes mellitus in 40% to 85% of patients, hypertension in 28% to 75% of patients, and dyslipidemia in 70% to 90% of patients. Rates of improvement in obesity comorbidities vary based on both the specific procedure performed and underlying patient characteristics. Together, these metabolic improvements may lead to reduced ASCVD risk and event rates. Indeed these observational cohort studies suggest bariatric surgery versus usual care may be associated with reduced number of cardiovascular deaths and lower incidence of cardiovascular events in obese adults, as well as reduced incidence of myocardial infarction in obese individuals with type 2 diabetes mellitus. Total mortality rates appear 30% to 40% lower in patients who have had bariatric surgery for obesity management and may be more prominent in those with diabetes mellitus at the time of surgery, although survival benefit effects may take years to manifest. Although key observational cohort controlled studies demonstrate mortality benefit, these data originate from nonrandomized trials and thus must be interpreted with extreme caution. Randomized, controlled clinical trials comparing effectiveness of bariatric surgery to nonsurgical medical management of type 2 diabetes mellitus are shorter in duration and have small numbers of participants but replicate observational studies for improvement in obesity and diabetes mellitus related comorbidities. Remission of type 2 diabetes mellitus may not be sustained and relapse requiring additional pharmacological therapy may become necessary. It remains uncertain whether long periods of metabolic improvement following bariatric surgery will improve cardiovascular or mortality outcomes, as suggested by longer term follow-up for the UKPDS, Steno-2, and the Swedish Obesity Subjects (SOS) study. However, it is reasonable for surgically-appropriate obese patients with type 2 diabetes mellitus to consider bariatric intervention, as associated surgical risks have decreased in the setting of more stringent standards and the formation of Bariatric Centers of Excellence, and with the reduction of short-term surgical risk due to laparoscopic versus open procedures. Thus, for patients with diabetes mellitus and BMI >35 kg/m² who have undergone appropriate medical and psychological evaluation, who understand the risks, lifestyle changes, and monitoring involved with bariatric surgery, and have medical, social, and psychological support, bariatric surgery can be recommended when performed by an experienced bariatric surgeon at a bariatric center of excellence. Interestingly, higher baseline fasting insulin, a proxy for insulin resistance, rather than higher BMI best predicts remission or improvement in type 2 diabetes mellitus and cardiovascular risk among patients without diabetes mellitus undergoing bariatric surgery.

Cardiovascular Risk of Diabetes Mellitus Drugs
The UKPDS showed a cardiovascular benefit for metformin, albeit in a relatively small number of individuals. Although concerns have been raised regarding increased cardiovascular risk with sulfonylureas in epidemiological studies, this has not been consistent, and intensive glycemic control using sulfonylureas in UKPDS did not demonstrate increased risk. Interestingly, over longer term observation, cardiovascular benefits were realized in the intensive group originally receiving sulfonylureas.

In 2008 the FDA issued a Guidance for Industry requiring that the approval of all new antidiabetic drugs rule out an unacceptable level of excess cardiovascular risk. From 1995 to this time, HbA1c was the sole efficacy end point for approval of anti–diabetes mellitus therapies. Randomized trials of new glycemic-lowering agents were typically 6 months in duration or less, with open label extension; the majority of patients enrolled in the trials were diabetes mellitus drug naïve, or had short duration of disease; cardiovascular disease and renal disease were often exclusionary; the safety databases had between 3000 to 5000 patients exposed (the majority <1 year), with longer-term experience uncontrolled; there were
sparse cardiovascular events and no central, blinded adjudication process for adverse experiences to facilitate meta-analysis across enabling trials. Thus, experience in the preapproval trials for new diabetes mellitus drugs differed substantially from the way drugs might be used in the broader population, especially relevant for patients with diabetes mellitus and cardiovascular disease, which co-occur with high prevalence. FDA concerns regarding diabetes mellitus drug development were furthered in part by a meta-analysis of several small trials suggesting excess risk with the drug rosiglitazone.\(^{280}\) Notably the Rosiglitazone Evaluated for Cardiovascular Outcomes in oral agent combination therapy for type 2 Diabetes (RECORD) trial\(^{102a}\) did not substantiate these concerns, even after readjudication of the cardiovascular events within the RECORD trial.\(^{371}\) Furthermore, the PROspective pioglitAzone Clinical Trial In macroVascular Events (PROActive) did not show increased ASCVD risk with pioglitazone.\(^{302}\)

For these reasons, in 2008 the FDA established a new guidance for industry for approval of diabetes mellitus therapeutic agents which remains in effect for all new diabetes mellitus drugs, including recently approved agents in multiple novel classes of GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT2 inhibitors, which have become available since implementation of the guidance process. The cardiovascular effects of glucose-lowering drugs have been reviewed recently by Ferrannini and DeFronzo.\(^{372}\) Recent cardiovascular outcome trials have shown a cardiovascular benefit with empagliflozin, an SGLT2 inhibitor\(^{373}\) and have been reported for liraglutide,\(^{374}\) a GLP-1 receptor agonist, although publication of trial data for the latter is still pending. No glucose-lowering agent studied under the guidance document has shown increased risk of MACE. Interesting and unexpected findings have come from these cardiovascular outcome trials. The DPP-4 inhibitor saxagliptin appears to modestly increase risk for hospitalization for heart failure without effect on major adverse cardiovascular events (see below section: Management of Diabetes Mellitus in Heart Failure).\(^{375}\)

SGLT1 and SGLT2 are the 2 sodium glucose cotransporters responsible for glucose reabsorption in the proximal tubule of the kidney.\(^{376}\) Inhibition of SGLT2 results in increased glucose transport to the distal nephron with reduction in renal hyperfiltration\(^{377}\) and lowering of the serum glucose threshold for renal reabsorption of glucose leading to excretion of 80 to 100 g of glucose per day.\(^{378}\) Three drugs in this class have been approved by the FDA for the treatment of diabetes mellitus: dapagliflozin, canagliflozin, and empagliflozin. Several other drugs in this class are in development. These drugs lower HbA\(_1c\) by 0.5 to 1.2% and do not cause hypoglycemia except when used with insulin provisional therapies (insulin or sulfonylureas).\(^{379}\) The SGLT2 inhibitors lower blood pressure without increasing heart rate, increase HDL and LDL cholesterol levels, and induce modest weight loss. The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG) study enrolled 7020 patients with type 2 diabetes mellitus at high risk for cardiovascular events, and randomized participants to receive empagliflozin 10 mg versus 25 mg versus placebo.\(^{373}\) The primary outcome was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, and the key secondary outcome was hospitalization for heart failure. The study was stopped early, with a mean observation time of 3.1 years. Empagliflozin resulted in a lower risk of the primary outcome (HR, 0.86; 95%, CI 0.74–0.99; \(P=0.04\) for superiority), lower risk of cardiovascular death, and all-cause mortality. Potential mechanisms for the reduction in cardiovascular risk found with empagliflozin include combined reductions in blood pressure, body weight (including visceral adiposity), albuminuria, glucose, arterial stiffness, sympathetic nervous system activation, oxidative stress, uric acid, diuresis, and improvement in cardiac function.\(^{379}\) Other potential mechanisms remain speculative including potential secondary effects on SGLT1\(^{380}\) and effects on mineralocorticoid metabolism.\(^{377}\) Whether this beneficial effect on cardiovascular outcomes is a class effect or a drug effect is unknown, and results of other cardiovascular outcome trials with SGLT2 inhibitors will not be available until 2017 for canagliflozin [CANagliflozin cardioVascular Assessment Study (CANVAS), NCT01032629] and 2018 for dapagliflozin [Dapagliflozin Effect on CardiovascularAR Events (DECLARE)-TIMI58, NCT01730534]. Until then, current evidence supports use of empagliflozin may reduce cardiovascular risk. Because of the beneficial effects on factors that play a role in cardiovascular risk such as weight, visceral fat, blood pressure, arterial stiffness, and albuminuria, the SGLT2 inhibitors may be preferred over other drug classes, although until the additional cardiovascular outcome trials are completed, this approach warrants continued caution. Furthermore, as with any other medical therapy, each individual patient’s comorbidities and complications must be considered prior to initiating SGLT2 inhibitor therapy. Potential adverse effects of SGLT2 inhibitor therapy include genitourinary infections, hypovolemia, “euglycemic” diabetic ketoacidosis, and skeletal fractures.

Importantly, these cardiovascular outcome trials conducted under the 2008 FDA Guidance are designed to evaluate safety of use of diabetes mellitus agents in patients with diabetes mellitus. Study populations enrolled are at especially high risk for or with underlying ASCVD, as this population is necessary to accrue sufficient events in a short period of time for study conduct. These studies do evaluate cardiotoxicity over short- to medium-term administration, but they do not address impact of early diabetes mellitus intervention, impact of long duration glycemic control, nor the merit of lowering glucose per se, as other anti–diabetes mellitus medications outside of the class under investigation are adjusted according to individual glucose goals, permitting assessment of possible drug-specific effects by minimizing potential confounding from differential glucose control.

Management of Diabetes Mellitus in the Setting of ASCVD

Because type 2 diabetes mellitus confers an increased risk of ASCVD, most diabetes mellitus patients without ASCVD fall into the moderate or high ASCVD risk category. Though some patients may fall into a lower risk category, all patients should undergo lifestyle intervention. Diabetes mellitus therapies should otherwise be selected on an individual basis, with special caution used when treating older patients. In the setting of known ASCVD, we recommend a treatment strategy that...
# Table 2. Glucose-Lowering Therapy: Key Clinical Considerations

<table>
<thead>
<tr>
<th>Class</th>
<th>Biguanide (Metformin is first choice unless contraindicated)</th>
<th>Glucagon-like peptide (GLP)-1 Receptor Agonist</th>
<th>Sodium-glucose cotransporter (SGLT) 2 Inhibitor</th>
<th>Dipeptidyl Peptidase (DPP) 4 inhibitor</th>
<th>Insulin Secretagogue (sufonylurea, meglitinide, or D-phenylalanine derivative)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estimated HbA1c reduction</td>
<td>1%</td>
<td>0.8–1.5%</td>
<td>0.5–0.6%</td>
<td>0.75%</td>
<td>0.75–1.25%</td>
</tr>
<tr>
<td>Agents</td>
<td>Metformin</td>
<td>Exenatide</td>
<td>Canagliflozin</td>
<td>Alogliptin</td>
<td>Glipizide</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Liroytide</td>
<td>Dapagliflozin</td>
<td>Linagliptin</td>
<td>Glyburide</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Albiglutide</td>
<td>Empagliflozin</td>
<td>Saxagliptin</td>
<td>Glimipride</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dulaglutide</td>
<td>Sitagliptin</td>
<td>Repaglinide</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Nateglinide</td>
<td></td>
</tr>
<tr>
<td>Route</td>
<td>Oral</td>
<td>Injectable</td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
</tr>
<tr>
<td>Actions</td>
<td>Decreases hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization</td>
<td>Increases glucose-dependent insulin secretion, lowers glucagon secretion, slows gastric emptying, and promotes satiety</td>
<td>Lowers the renal threshold for glucose reabsorption to increase urinary glucose excretion</td>
<td>Blocks inactivation of incretin hormones to increase insulin release and decrease glucagon in a glucose-dependent manner</td>
<td>Stimulates insulin release from pancreatic β cells.</td>
</tr>
<tr>
<td>Side Effects</td>
<td>Diarrhea, nausea/vomiting, flatulence, vitamin B12 deficiency, lactic acidosis</td>
<td>Nausea, diarrhea, possible pancreatitis</td>
<td>Polyuria, urinary frequency, hypovolemia, genital and urinary tract infections, hyperkalemia. Reported diabetic ketoacidosis with serum glucose as low as 200 mg/dL</td>
<td>Occasional gastrointestinal discomfort, upper respiratory tract complaints</td>
<td>Hypoglycemia</td>
</tr>
<tr>
<td>Contraindications</td>
<td>Chronic kidney disease with eGFR&lt;30 mL/min; Acidosis; Alcohol excess; severe congestive heart failure; hypovolemia. If IV contrast to be used, hold on day of study and restart 48 h after IV contrast if eGFR&gt;45 mL/min</td>
<td>History of pancreatitis. Personal or family history of medullary thyroid cancer or MEN2. Do not use with DPP4 inhibitors.</td>
<td>Severe renal disease with eGFR&lt;30 mL/min, use with caution in patients with bladder cancer</td>
<td>History of pancreatitis. Do not use with GLP-1 receptor agonists.</td>
<td>Severe liver or renal disease</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Drug/Agent</th>
<th>Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thiazolidinedione (TZD)</td>
<td>α-Glucosidase Inhibitor</td>
<td>Bile Acid Sequestrant</td>
</tr>
<tr>
<td>pioglitazone</td>
<td>oral</td>
<td>1.0–1.25%</td>
</tr>
<tr>
<td>acarbose</td>
<td>oral</td>
<td>0.5–1.0%</td>
</tr>
<tr>
<td>miglitol</td>
<td>oral</td>
<td>0.5–1.0%</td>
</tr>
<tr>
<td>miglitol</td>
<td>injectable</td>
<td>0.5–1.0%</td>
</tr>
</tbody>
</table>

- Activates PPARγ, increases peripheral glucose utilization, and decreases hepatic glucose production.
- Reduces absorption of dietary carbohydrate.
- Uncertain mechanism of glucose lowering; binds bile acids in intestine, impeding their reabsorption and increasing LDL-C clearance.
- Uncertain mechanism of glucose lowering with increased insulin sensitivity and glucose disposal.
- Slows gastric emptying, reduces glucagon secretion, and increases satiety.
- Weight gain, edema, congestive heart failure in patients with underlying disease.
- Gastrointestinal discomfort, flatulence, diarrhea, elevated transaminases.
- Gastrointestinal discomfort, reduces gastric absorption of some drugs.
- Gastrointestinal discomfort, headache.
- Gastrointestinal discomfort, headache.

- Severe heart disease at risk for CHF, NYHA Class III or IV heart failure, liver disease. Caution in patients with macular edema.
- Chronic intestinal disorders, moderate to severe renal impairment (creatinine >2 mg/dL), caution in cirrhosis.
- Serum triglyceride >500 mg/dL; History of hypertriglyceridemia-related pancreatitis, bowel obstruction.
- Lactating women, syncopal migraines or use of ergot class of medications.
- Gastroparesis. Do not use with α-glucosidase inhibitors, may delay absorption of concomitant medications.

- Increased risk for bone fractures. Increased fluid retention. Rosiglitazone is not inferior for cardiovascular outcomes (RECORD). Pioglitazone is neutral to beneficial for composite cardiovascular outcomes (PROACTIVE).
- May reduce cardiovascular risk in patients with impaired glucose tolerance (STOP-NIDDM).
- Lowers LDL-C.
- Reduced cardiovascular events in FDA enabling trials (Cycloset™ Safety Trials).
primarily focuses on cardiovascular risk reduction (Table 1). Regarding glycemic control, a goal HbA1c \( \leq 7.0\% \) is recommended by the authors if multiple diabetes mellitus drugs are tolerated, and polypharmacy does not diminish intensity of cardiovascular risk management; however, if this is not the case, a less intensive goal of HbA1c \( \leq 7.5\% \) is recommended. For patients at high risk of ASCVD, an HbA1c \( \leq 7.0\% \) would be reasonable, if this can be achieved with minimal hypoglycemia. For patients without known ASCVD who are at moderate risk, an aggressive goal of HbA1c \( \leq 6.5\% \) will substantially reduce the risk for microvascular complications and may contribute to eventual reduction in ASCVD.\(^{41}\)

Multiple factors must be considered in the selection of diabetes mellitus medications for patients with ASCVD. The strong data supporting the effect of glucose-lowering to reduce microvascular disease which has a direct impact on cardiovascular risk (especially albuminuria) and eventual long-term reduction in ASCVD over 20 years (from the UKPDS follow-up study) must be balanced against potential acute effects of hypoglycemic episodes, increased risk of heart failure (thiazolidinediones and potentially select DPP-4 inhibitors) and weight gain (sulfonylureas, insulin), other side effects, and cost. On a background of lifestyle interventions, the first-line pharmacological therapy for glucose-lowering should be metformin, if renal function is adequate (Table 2),\(^{381-386}\) and noting recently revised 2016 FDA guidance for renal safety of metformin.\(^{387}\) eGFR should be assessed before initiation of metformin and at least annually for patients using metformin and more frequently for patients at increased risk for renal impairment; starting metformin is generally not recommended for those with eGFR between 30 to 45 mL/min/1.73m\(^2\) but may be continued in this range for those already on the drug when the benefit supports ongoing use; for those with or developing eGFR \( \leq 30\) mL/min/1.73m\(^2\) metformin should be discontinued. In addition to those with heart failure, liver disease, or alcoholism, treatment with metformin should be discontinued at the time of iodinated contrast imaging and resumed if renal function is stable when reassessed after 48 hours.

In light of the EMPA-REG trial results with empagliflozin\(^{275}\) and early reports on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results – A Long Term Evaluation (LEADER) trial with liraglutide reducing major adverse cardiovascular event rates,\(^{374}\) the next drug to be considered in a patient with persistent hyperglycemia despite adherence to lifestyle and metformin might include either these specific drugs or SGLT2 inhibitors or GLP-1 receptor agonists class agents. Although only top-line results are available for LEADER, details supporting these findings are anticipated shortly. Interestingly a neutral cardiovascular profile was seen in the Evaluation of LIXisenatide in Acute Coronary Syndrome (ELIXA) trial with lixisenatide,\(^{382}\) currently approved by the European Medicines Agency, and additional review of the data are needed to help determine whether key aspects of study design underlie potential differences in findings between trials or whether differences between class agents may be important. DPP-4 inhibitors are an option except possibly in individuals with heart failure, as discussed in the next section on heart failure.\(^{386}\) Prioritization for sulfonylureas is lower in the setting of ASCVD because of the risk for hypoglycemia, although with careful monitoring and in selected patients, these agents are a reasonable choice, especially in those with higher baseline HbA1c in whom hypoglycemia is less likely to occur. Insulin is often needed to achieve glycemic targets and has not been shown to increase ASCVD risk,\(^{387}\) although it carries a high risk of hypoglycemia and increases renal sodium retention.\(^{388-390}\) The BARI-2D trial showed that an insulin sparing strategy did not confer a cardiovascular benefit, but because of the aforementioned concerns, a basic paradigm of insulin sparing (reduction in insulin dose or discontinuation of insulin preferentially before reducing or stopping other diabetes mellitus medications) is generally recommended, recognizing that insulin provision therapy is frequently necessary with longer duration of disease and may be preferred when multiple agents are required to maintain glycemic targets.

For patients requiring multiple agents to achieve their individualized HbA1c goal, a strategy for prioritizing management of diabetes mellitus in the setting of CV risk reduction is needed. A suggested approach by the authors is outlined in Table 1. An overview of diabetes mellitus treatment including available classes of glucose-lowering agents, magnitude of HbA1c lowering, mechanisms of action, side effects, and key clinical considerations is included in Table 2. Published randomized, controlled trials of cardiovascular outcomes for glucose-lowering agents are outlined in Figure 5.\(^{391-396}\)

**Epidemiology of Diabetes Mellitus and Heart Failure**

Heart failure has been called “the frequent, forgotten, and often fatal complication of diabetes mellitus.”\(^{397}\) Risk for heart failure increases 2.4-fold in men and 5-fold in women in comparison with those without diabetes mellitus, as seen in the Framingham Heart Study.\(^{398}\) Conversely, diabetes mellitus is an important predictor of heart failure, independent of concomitant hypertension or coronary artery disease.\(^{398}\) Subsequent studies confirm higher prevalence of heart failure, incident diagnosis of new heart failure in patients without baseline heart failure, and risk of heart failure hospitalization or death among patients with compared to those without diabetes mellitus.\(^{399-403}\) Heart failure is the second most common manifestation of cardiovascular disease after peripheral arterial disease, as demonstrated in the largest cohort study of almost 1.9 million patients with type 2 diabetes mellitus followed for a median of 5.5 years.\(^{404}\) Multiple factors, including age, ischemic heart disease, and peripheral artery disease, as well as diabetes mellitus—specific risk factors, such as poor glycemic control (higher HbA1c) and insulin resistance, have been associated with heart failure in patients with diabetes mellitus.\(^{36,401-403,405-407}\) Accelerated atherosclerosis of diabetes mellitus may be diffuse and severe. Consequently, ischemic cardiomyopathy is a major cause of heart failure in the diabetes mellitus population. Even in the absence of epicardial coronary artery disease, microvascular disease, characterized by arterial thickening and fibrosis, as well as endothelial and vasomotor dysfunction, can increase risk of heart failure in diabetes mellitus. Hypertension is another common comorbid condition in diabetes mellitus, causing left ventricular hypertrophy and contributing to the development of heart failure.\(^{408}\)
The relationship between diabetes mellitus and heart failure appears bidirectional. There is increased risk of heart failure in diabetes mellitus, and heart failure is a risk factor for diabetes mellitus. Increased rates of diabetes mellitus occur among patients with heart failure: 42% of 48,612 patients hospitalized with heart failure in the Organized Program To Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) registry and 40% of hospitalized patients with low ejection fraction in the Evolve Cardiovascular Valve Repair (MitraClip) System Endovascular Valve Edge-to-Edge REPair STudy (EVEREST) had diabetes mellitus. The presence of diabetes mellitus in hospitalized heart failure patients is associated with worse outcomes, including longer hospital stay, heart failure–related rehospitalization, and greater risk of cardiovascular mortality. Among stable outpatients with heart failure, diabetes mellitus remains an independent predictor of heart failure hospitalization and cardiovascular mortality after adjusting for left ventricular ejection fraction. Even in the absence of overt diabetes mellitus, up to two-thirds of heart failure patients exhibit insulin resistance, which not only increases the risk of subsequent diabetes mellitus but also independently predicts poor prognosis in patients with heart failure.

In 1954, Lundbaek made the initial observation that myocardial dysfunction was common in elderly patients with diabetes mellitus, and he termed this phenomenon “diabetic cardiopathy.” Almost 2 decades later, Rubler reported postmortem findings from 4 patients with diabetes mellitus and heart failure in the absence of significant epicardial coronary atherosclerosis, valvular, congenital, or hypertensive heart disease, or alcoholism. He described myocardial hypertrophy, fibrosis, and microvascular wall thickening and proposed a diabetes mellitus–related cardiomyopathy caused by abnormal myocardial metabolism or myocardial microangiopathy. These observations stimulated basic and clinical studies examining phenotypes and pathophysiologic mechanisms of diabetes mellitus–related cardiomyopathy. Despite efforts to understand diabetic cardiomyopathy, there is ongoing controversy surrounding its unique pathophysiology, and it remains a vaguely-defined condition only briefly acknowledged in contemporary clinical practice guidelines. Furthermore, although diabetes mellitus is now accepted as an independent cause of cardiomyopathy, severity of diabetes mellitus–related myocardial abnormalities may be amplified by comorbid conditions which increase the risk of ventricular hypertrophy or susceptibility to myocardial ischemia, ultimately increasing the risk for heart failure.

**Diabetic Cardiomyopathy – Clinical Phenotype**

The natural history of diabetic cardiomyopathy remains incompletely understood. Experimental animal models of diabetes mellitus and cardiac imaging–based human studies demonstrate both diastolic and systolic dysfunction. Traditionally, diabetic cardiomyopathy has been characterized as a progressive disease beginning with subtle, early features of impaired diastolic dysfunction followed by overt diastolic dysfunction, with or without ventricular hypertrophy. Thus, diastolic dysfunction is the hallmark characteristic of diabetic cardiomyopathy, with systolic dysfunction representing the final stage of progressive disease. Depressed pressure development and decay rates and prolonged cardiac relaxation times occur as early as 2 to 3 weeks after streptozotocin-induced diabetes mellitus in rats, before left ventricular remodeling, supporting this diastolic-dysfunction hypothesis. Human studies similarly demonstrate early abnormalities in diastolic function, including reduced peak myocardial systolic and early diastolic velocities, seen in 27% to 70% of asymptomatic patients with diabetes mellitus without overt diastolic dysfunction or LV hypertrophy, as well as greater LV mass, wall thickness, and arterial stiffness (independent of blood pressure and body mass index) in diabetes mellitus patients. Clinically, patients with diabetic cardiomyopathy and diastolic dysfunction initially present with a restrictive phenotype as heart failure with preserved ejection fraction (HFrEF).

However, diabetic cardiomyopathy can also present with systolic dysfunction and a dilated phenotype as heart failure with reduced ejection fraction (HFrEF). In animal models, diabetes mellitus has been associated with systolic dysfunction, with longer duration of diabetes mellitus necessary for development of reduced ejection fraction. These findings are paralleled by human studies in which diabetes mellitus is associated with a significant increase in the odds of idiopathic dilated cardiomyopathy (OR, 1.75; 95% CI, 1.71–1.79). Additionally, left ventricular systolic dysfunction can be induced with exercise in asymptomatic patients with diabetes mellitus and normal resting ejection fraction, perhaps representing reduced cardiac reserve and an early, preclinical phase of systolic dysfunction. It is also hypothesized that subtle impairments in longitudinal systolic function may be missed because the traditional focus on radial myocardial contraction and more sensitive techniques, such as strain and myocardial tissue Doppler velocity, may better detect early systolic abnormalities in patients with diabetes mellitus. Taken together, these data suggest a spectrum of diabetic cardiomyopathy.

Recently, Seferovic and Paulus proposed a new paradigm in which restrictive and dilated manifestations of diabetic cardiomyopathy are two distinct clinical phenotypes rather than successive stages. This conceptual shift is based on multiple lines of evidence. Normal age-related cardiac remodeling is characterized by decreasing left ventricular dimensions and increasing fractional shortening, a pattern attenuated but not reversed by diabetes mellitus. Furthermore, development of symptoms in hypertensive patients with HFrEF is associated with a reduction, not dilatation, of the left ventricle. In the general HFrEF population, progression to a dilated phenotype is uncommon; when it occurs, it is often related to myocardial infarction or older age but not diabetes mellitus. Finally, differential mechanisms of left ventricular remodeling specific to HFrEF versus HFrEF have been proposed.

Thus, diastolic dysfunction may not be a precursor to systolic dysfunction; rather, specific mechanisms with selective involvement of endothelial cells versus myocytes in diabetes mellitus–related metabolic and cellular disturbances may account for the independent evolution of 2 distinct forms of diabetic cardiomyopathy.
Figure 5. Randomized, controlled, cardiovascular outcome trials of glucose-lowering drugs or strategies in people with type 2 diabetes mellitus. ACS indicates acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease including myocardial infarction or ischemic stroke; CV risk, increased risk for cardiovascular disease based on risk factors, but not ischemic ASCVD; HR, hazard ratio; MACE, major adverse cardiovascular event: cardiovascular mortality, myocardial infarction, stroke; RRR, relative risk reduction; SFU, sulfonylurea; and T₂DM, type 2 diabetes mellitus. Studies: ACCORD indicates Action to Control Cardiovascular Risk in Diabetes; ACCORDION, ACCORD Follow-on study; ADDITION, Intensive Treatment in People With Screen Detected Diabetes; ADVANCE, Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation; BAY29-805, BAY-29-805; BARDO, Genetics; CAMELIA, Clinical Evaluation of Action with Liraglutide for Cardiovascular Protection; CAROLINA, Cardiac Risk in Diabetes; CARDIOGRAM, Cardiac Outcomes Assessment with Ramipril and厄贝沙坦 in Diabetes; CANTOS, Cardiovascular Assessment of the Effects of Anacetrapib Compared to Placebo on Top of Statin Therapy; CECOP, Comparison of Oral Glitazone and Insulin Treatment Strategies in Patients With Type 2 Diabetes; COMET, Cardiovascular Outcomes in the Evaluation of Carintriptan for the Management of Episodic Migraine; ELIXA, Evaluation of LiXisenatide in Patients With Type 2 Diabetes Mellitus; EXAMINE, Evaluation of Exenatide in Patients With Type 2 Diabetes Mellitus; LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of Carbohydrate Metabolism; NGF1, Nateglinide and Glibenclamide in Subjects With Type 2 Diabetes Mellitus; VELLOTO, Vali
tropin and insulin treatment; VISTA, Valsartan in Patients at Risk of Cardiovascular Events; VYXLOGEN, Vary of Hypoglycaemic Agents on Glycaemic Control in Patients With Type 2 Diabetes Mellitus; WAVE, Worsening of Metabolic Control With Increasing Incretin Activity during Infusion; WOEST, Continuous Glucose Monitoring With an Insulin Pump in Type 2 Diabetes Mellitus; XCEED, Xeloda in the Treatment of Type 2 Diabetes Mellitus; XODA, Xigduo, a fixed-dose combination of Dymelor, a dipeptidyl peptidase IV inhibitor, and Metformin, a thiazolidinedione; XU2, Xian Long; Yudenda, Yudenda; ZINC, The ZIPT2 Incretin Effect in Type 2 Diabetes; and ZYNTEGEL, Zynptegel. T2DM indicates type 2 diabetes mellitus; N-terminal pro-B-type natriuretic peptide and NT-proBNP indicate N-terminal pro-B-type natriuretic peptide and natriuretic peptide, respectively; and SFU, sulfonylurea; and T2DM, type 2 diabetes mellitus. Studies: ACCORD indicates Action to Control Cardiovascular Risk in Diabetes 333; ACCORDION, ACCORD Follow-on study; ADDITION, Intensive Treatment in People With Screen Detected Diabetes; ADVANCE, Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation; BAY29-805, BAY-29-805; BARDO, Genetics; CAMELIA, Clinical Evaluation of Action with Liraglutide for Cardiovascular Protection; CAROLINA, Cardiac Risk in Diabetes; CARDIOGRAM, Cardiac Outcomes Assessment with Ramipril and厄贝沙坦 in Diabetes; CANTOS, Cardiovascular Assessment of the Effects of Anacetrapib Compared to Placebo on Top of Statin Therapy; CECOP, Comparison of Oral Glitazone and Insulin Treatment Strategies in Patients With Type 2 Diabetes; COMET, Cardiovascular Outcomes in the Evaluation of Carintriptan for the Management of Episodic Migraine; EXAMINE, Evaluation of Exenatide in Patients With Type 2 Diabetes Mellitus; LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of Carbohydrate Metabolism; NGF1, Nateglinide and Glibenclamide in Subjects With Type 2 Diabetes Mellitus; VELLOTO, Vali
tropin and insulin treatment; VISTA, Valsartan in Patients at Risk of Cardiovascular Events; WAVE, Worsening of Metabolic Control With Increasing Incretin Activity during Infusion; WOEST, Continuous Glucose Monitoring With an Insulin Pump in Type 2 Diabetes Mellitus; XCEED, Xeloda in the Treatment of Type 2 Diabetes Mellitus; XODA, Xigduo, a fixed-dose combination of Dymelor, a dipeptidyl peptidase IV inhibitor, and Metformin, a thiazolidinedione; XI2, Xian Long; Yudenda, Yudenda; ZINC, The ZIPT2 Incretin Effect in Type 2 Diabetes; and ZYNTEGEL, Zynptegel. T2DM indicates type 2 diabetes mellitus; N-terminal pro-B-type natriuretic peptide and NT-proBNP indicate N-terminal pro-B-type natriuretic peptide and natriuretic peptide, respectively; and SFU, sulfonylurea; and T2DM, type 2 diabetes mellitus. Studies: ACCORD indicates Action to Control Cardiovascular Risk in Diabetes 333; ACCORDION, ACCORD Follow-on study; ADDITION, Intensive Treatment in People With Screen Detected Diabetes (Continued)
The pathogenesis of diabetic cardiomyopathy is complex and multifactorial. Although hyperglycemia and insulin resistance are the main physiological disturbances in diabetes mellitus, multiple mechanisms, such as derangements in cellular metabolism, function, and structure, autonomic neuropathy, and neurohormonal dysregulation are believed to play a role in the associated cardiomyopathy (Figure 6). Diabetic cardiomyopathy can be primarily traced to multiple processes: oxidative stress, hyperglycemia, hyperinsulinemia, or hyperlipidemia, but no consensus exists regarding a unifying pathophysiologic hypothesis. A general overview of major contributing mechanisms is discussed herein, although the reader is referred to comprehensive reviews focused solely on diabetes mellitus–related heart failure for additional information.

**Metabolic Perturbations**

Major energy sources for cardiac metabolism include glucose and free fatty acids. Free fatty acids are preferentially utilized in the fasting state, whereas glucose is the substrate of choice in the postprandial state or under conditions of stress or ischemia. Healthy cardiomyocytes are able to switch between these sources to accommodate different physiological conditions. In patients with diabetes mellitus, insulin resistance and hyperglycemia cause downregulation of myocardial glucose transporters (primarily GLUT4 in adults), reduced glucose oxidation, and an increase in fatty acid oxidation and levels of free fatty acids. A higher oxygen requirement of fatty acid oxidation compared with glucose metabolism leads to relative cardiac ischemia, resulting in an accumulation of lactate and impaired calcium homeostasis and myocyte contraction. Additionally, elevated levels of free fatty acids cause lipid accumulation in cardiomyocytes and lipotoxicity, which manifests as contractile dysfunction and eventual cardiomyocyte apoptosis.

**Functional Alterations**

Impaired calcium handling in cardiomyocytes is a key feature of diabetic cardiomyopathy. In the normal state, excitation-contraction coupling of cardiomyocytes is mediated by several intracellular calcium transporters, including the ryanodine receptor, and relaxation occurs via the ejection of calcium from the sarcoplasmic reticulum.
calcium from the cell through the sarcoplasmic reticulum calcium pump 2a (SERCA2a), the sodium-calcium exchanger, and the plasma membrane calcium ATPase. Animal models of diabetes mellitus have altered expression, activity, and function of all of these transporters. 

Reduced SERCA2a activity and consequent calcium overload in the cytosol can cause impaired relaxation as well as altered calcium sensitivity of proteins involved in regulation of the cardiac actomyosin system and shifting of cardiac myosin heavy chain isoforms from V1 to V3, which can lead to reduced contractile force.

Mitochondrial dysfunction and increased oxidative stress contribute to the pathogenesis of diabetic cardiomyopathy. Proposed mechanisms for diabetes mellitus–related mitochondrial dysfunction include fatty acid–induced mitochondrial uncoupling leading to increased myocardial oxygen consumption and reduced cardiac efficiency, impaired mitochondrial calcium handling, and mitochondrial proteomic remodeling via post-translational modifications of mitochondrial proteins. Hyperglycemia can cause mitochondrial production of superoxide in endothelial cells. Although increased production of reactive oxygen species occurs mainly in mitochondria, cytosolic systems, such as NAPDH oxidase, can also generate reactive oxygen species and increase oxidative stress, potentially contributing to diabetic cardiomyopathy via accelerated apoptosis, cardiac hypertrophy, fibrosis, subcellular remodeling, and impaired calcium handling.

Structural Changes
Cardiomyocyte hypertrophy is common in diabetic cardiomyopathy and may result from insulin resistance and cell growth in response to hyperinsulinemia, as occurs in type 2 diabetes mellitus. This observation has led to concern about the use of insulin but has not been born out in clinical trials. In contrast, patients with type 1 diabetes mellitus more frequently exhibit hyperglycemia–related myocardial fibrosis rather than hypertrophy. Fibrosis may be related to the formation of AGEs, comprising cross-linked collagen which may deposit in arterial walls, myocardium, and endothelial cells. Higher serum levels of AGEs are associated with greater ventricular isovolumetric relaxation times, a marker of diastolic dysfunction, and greater arterial stiffness. Deposition of AGEs in arterioles may also result in microvascular remodeling and angiopathy characterized by capillary basement membrane thickening and formation of microaneurysms, leading to subsequent impairment of nitric oxide production. Subsequent endothelial dysfunction from decreased NO bioavailability and endothelial damage from high glucose exposure may explain the reduced coronary blood flow reserve and myocardial hypertrophy observed in diabetic cardiomyopathy.

Cardiac Autonomic Neuropathy
Under normal conditions, sympathetic stimulation causes vasodilation of coronary resistance vessels and improves left ventricular contraction and left ventricular relaxation rates. Cardiac autonomic neuropathy in diabetes mellitus is characterized by sympathetic denervation, depletion of myocardial catecholamine stores, and functional impairment in cardiac sympathetic nerve fibers. Each of these processes may contribute to left ventricular systolic and diastolic dysfunction and reduced 8-year survival among patients with cardiac autonomic neuropathy in comparison with those with normal autonomic function (77% versus 97%, respectively).

Neurohormonal Activation
Neurohormonal abnormalities are present in both diabetes mellitus and heart failure. There is early activation of RAAS in diabetes mellitus, leading to overproduction of angiotensin II and supporting the blood pressure trials discussed above. Excess angiotensin II and aldosterone production induce cardiac hypertrophy and fibrosis via collagen deposition and fibroblast proliferation, as well as oxidative damage and cellular apoptosis. In addition, angiotensin II may cause myocardial ischemia through calcium overloading in cardiomyocytes. These effects of angiotensin II and aldosterone, which clinically manifest as diastolic dysfunction, are intensified by hyperglycemia and compounded by renin stimulation related to sympathetic nervous system overactivity observed in heart failure.

Management of Heart Failure in Diabetes Mellitus
Multiple pharmacological and device therapies have proven benefits and are recommended for the treatment of chronic heart failure. In chronic heart failure trials, up to 30% of participants generally have comorbid diabetes mellitus, and subgroup analyses have not demonstrated significant differences in treatment effects among diabetes mellitus patients. Despite previous concern regarding β-blocker use in diabetes mellitus resulting from potential masking of hypoglycemia and adverse effects on insulin resistance, current literature supports use of β-blockers in the treatment of heart failure among diabetes mellitus patients. Similarly, beneficial effects of ACE inhibitors, angiotensin-receptor blockade, mineralocorticoid-receptor antagonism, and cardiac resynchronization therapy are demonstrated among heart failure patients with diabetes mellitus. Although use of diuretic medications has been associated with impaired glucose tolerance potentially related to hypokalemia or visceral fat deposition, these drugs are often necessary to treat stable and acutely decompensated heart failure patients; no studies have examined differential effects of these medications according to diabetes mellitus status. Based on available data, management of heart failure patients with diabetes mellitus should follow standard treatment guidelines for the general heart failure population.

Management of Diabetes Mellitus in Heart Failure
Although heart failure management is not different in patients with diabetes mellitus, special consideration should be taken in glycemic management as effects on heart failure differ among agents. Studies to date suggest that SGLT2 medications appear to be safe from a cardiovascular perspective, and empagliflozin reduces the relative risk for heart failure hospitalization by 35% (HR 0.65, 95% CI 0.50, 0.85) in comparison with placebo in high-risk cardiovascular patients with type 2 diabetes.
diabetes mellitus. Possible mechanisms for this observation include osmotic diuresis and reduced arterial stiffness caused by SGLT-2 inhibition leading to lower plasma volume and blood pressure, as well as altering tubular-glomerular feedback mechanisms, or indirect effect on SGLT1, the transporter primarily responsible for intestinal glucose absorption. As with cardiovascular mortality effects, whether this heart failure benefit is a class effect is not yet known and will be evaluated in the ongoing studies Canagliflozin Cardiovascular Assessment Study (NCT01032629) and Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (NCT01730534).

Potential cardiovascular effects of incretin-based diabetes mellitus treatments in patients with heart failure are not well understood. Incretin mimetics improve glycemia by increasing glucose-dependent insulin secretion, lowering glucagon, inhibiting gluconeogenesis, and increasing insulin sensitivity, while promoting weight loss. In endothelial cells and myocytes, the incretin hormone GLP-1 may have cardioprotective effects, including vasodilatory and anti-inflammatory properties, independent of its antihyperglycemic action. GLP-1 also has been shown to reduce blood pressure via an atrial natriuretic pathway. Previous data have suggested that GLP-1 is involved in maintaining normal cardiac structure and function, as evidenced by the increased thickness, impaired contractility, and elevated end diastolic pressure of the left ventricle, as well as diastolic dysfunction and reduced cardiac reserve observed in knockout mice deficient in the GLP-1 receptor. However, this hypothesis has been challenged recently by studies in which experimental murine models of myocardial infarction and heart failure have not been affected by lack of GLP-1 receptor expression. The cardiovascular outcome trial with the GLP-1 receptor agonist lixisenatide, which is not available data suggest safe use of GLP-1 receptor agonists in patients with heart failure, although additional studies using are ongoing. Recently, the Effect of Exenatide Compared with Insulin Glargine on Cardiac Function and Metabolism of Type 2 Diabetic Patients with Congestive Heart Failure: A Randomized Comparator-controlled Trial (NCT00766857) comparing the effect of exenatide versus insulin glargine on left ventricular ejection fraction was completed, but results have not yet been published. Further insight will come from the LEADER trial with liraglutide, and the Exenatide Study of Cardiovascular Event Lowering Trial (NCT01144338), a placebo-controlled, randomized study of ≈14000 patients that will examine the effects of exenatide on cardiovascular outcomes, including heart failure hospitalizations. To date, available data suggest safe use of GLP-1 receptor agonists in patients with heart failure.

Three large randomized cardiovascular outcome trials of DPP-4 inhibitors in comparison with placebo have now been reported, and effects on heart failure are inconsistent. In the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) in 14671 persons with type 2 diabetes mellitus and established preexisting vascular disease, hospitalization for heart failure rates were similar in sitagliptin compared with placebo groups, 3.1% sitagliptin versus 3.1% placebo: hazard ratio 1.00 (95% CI, 0.83–1.20). The hazard ratio for hospitalization for heart failure was similar in the sitagliptin-treated group in those with baseline history of heart failure, although absolute rates were higher. In contrast, the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-Thrombolysis in Myocardial Infarction (TIMI) 53 trial, which randomized 16492 participants with established cardiovascular disease or increased cardiovascular risk, demonstrated an unanticipated increased risk of heart failure in the saxagliptin-treated group: event rate 3.5% in saxagliptin versus 2.8% in placebo (HR, 1.27; 95% CI, 1.07–1.51), in the setting of noninferiority for the primary cardiovascular outcome (cardiovascular death, myocardial infarction, stroke). In this trial, heart failure was a prespecified individual clinical end point within the major secondary composite cardiovascular outcome. Increased hospitalization for heart failure was primarily observed in those with highest baseline N terminus of the prohormone brain natriuretic peptide (NT-proBNP) concentration. The smaller, shorter trial EXamination of cArdiovascular outcoMes with alogliptIN versus standard of care (EXAMINE) with randomization of 5380 higher risk acute coronary syndrome patients demonstrated a nonstatistically significant trend with similar point estimate seen in the SAVOR-TIMI 53 trial of saxagliptin toward increased heart failure in the alogliptin-treated group: event rate 3.9% alogliptin versus 3.3% placebo (HR, 1.19; 95% CI, 0.89–1.58), also in the setting of noninferiority for the primary cardiovascular outcome (cardiovascular death, myocardial infarction, stroke). Hospitalization for heart failure was not increased in the alogliptin-treated group in those with history of heart failure or higher baseline B-type natriuretic peptide (BNP) concentration.

Increased risk of hospitalization for heart failure was not consistent across SAVOR-TIMI 53, EXAMINE, and TECOS. These were not head-to-head comparisons of the 3 DPP-4 inhibitors, and caution should be applied when comparing agents. There were differences in patient illness severities, comorbidities, and concomitant therapies, sample size and duration of follow-up, and the potential for altered attentiveness and therapeutic practices attributable to baseline differences, or variation in definition or acquisition of heart failure events across trials. It is possible that there are intrinsic pharmacological differences between the DPP-4 inhibitors in specificities on or off target. However, it is also possible that heart failure is a class effect, as a test for heterogeneity for hospitalization for congestive heart failure across trials was not significant. There are plausible mechanisms for increased heart failure with DPP-4 inhibition. DPP-4 cleaves additional protein substrates beyond the incretins GLP-1 and glucose-dependent insulinotropic peptide, and multiple DPP-4 substrates have been identified which may influence the cardiovascular system, including
natriuretic peptide which is inactivated by DPP4 and provides a plausible mechanism for altered fluid balance.460 Alternatively, in preclinical models, diabetic mice treated with the potent DPP-4 inhibitor MK-0626 exhibit modest cardiac hypertrophy, impairment of cardiac function, and dysregulated expression of genes and proteins controlling inflammation and cardiac fibrosis.467 A recent multinational multicenter observational study of use of incretin based drugs and heart failure involving ≈1.5 million persons finds no association of incretin-based therapies with heart failure as compared with combinations of oral antidiabetes drugs, although both DPP-4 inhibitors and GLP-1 receptor agonists were combined in this analysis and comparative risk of specific agents was not possible.468 As heart failure is common in patients with type 2 diabetes mellitus, providers must select therapeutic agents for the totality of their risk benefit, and in the setting of noninferiority for major adverse cardiovascular events, watch for signs and symptoms of heart failure in their patients. Several diabetes mellitus medications should be used with caution in patients with concomitant heart failure. Thiazolidinediones increase insulin sensitivity by activating the peroxisome proliferator-activated receptor (PPAR)-γ. In meta-analyses of randomized clinical trials, patients treated with thiazolidinediones versus placebo had an increased risk of heart failure (OR up to 2.1; 95% CI, 1.08–4.08).489–491 Observational data suggest the risk for heart failure appears higher with rosiglitazone than pioglitazone.492 Although not approved for clinical use, aleglitazar, a dual PPAR-α and -γ agonist, also increased the risk of heart failure by 22% in the Aleglitazar Acute Coronary Syndrome and Type 2 Diabetes Mellitus (Ale Cardio) trial.493 Thiazolidinediones have not been shown to have adverse effects on ventricular remodeling or ventricular contractility and function.494 Instead, thiazolidinedione-related heart failure may be attributable to fluid retention from PPAR-γ stimulation of sodium reabsorption in renal epithelial sodium channels.495–497 In contrast with the setting of HFrEF, volume retention from thiazolidinediones is typically early, not progressive, and responsive to withdrawal of therapy.495,496 Thiazolidinediones have an FDA-issued black box warning and are contraindicated in patients with New York Heart Association class III through IV heart failure. They should be used cautiously in patients with class I through II heart failure with close monitoring for fluid retention.347

Insulin therapy can also stimulate sodium retention and has been associated with edema.490 In vitro and animal studies have shown that insulin increases the activity of renal sodium transporters, though clinical studies suggest the main effect is in the distal tubule via the same epithelial sodium channel stimulated by thiazolidinediones.500 Consequently, the risk of edema is greater when insulin and thiazolidinediones are given together (5% with single therapy versus 13% to 16% in combination).500 Insulin use in heart failure patients has been associated with worse prognosis, including increased all-cause mortality, cardiovascular mortality, and heart failure hospitalizations.489,501,502 This relationship may be confounded by the use of insulin later in the course of type 2 diabetes mellitus, and increased heart failure was not seen in the Outcome Reduction With Initial Glargine Intervention (ORIGIN) trial, where insulin glargine was used earlier in disease, and a trend toward decreased risk of heart failure hospitalization was observed.347

Other diabetes mellitus drug classes with potentially deleterious effects in heart failure include biguanides and sulfonylureas. Metformin is a first-line treatment for diabetes mellitus. However, the FDA issued a black box warning against the use of metformin in heart failure patients requiring pharmacological management because of a risk of lactic acidosis.503 The risk of lactic acidosis is small and related to decreased drug clearance in the setting of hypoperfusion or renal dysfunction, both of which may be worsened in acute heart failure exacerbations. Although metformin-related lactic acidosis has been reported,504 observational data suggest that metformin use in patients with stable chronic heart failure is associated with a mortality benefit without excess risk of lactic acidosis.505 Metformin may thus be used with caution in heart failure patients with stable renal perfusion and an adequate glomerular filtration rate. The data for sulfonylureas are also mixed and report variable associations between increased risk of heart failure and first- and second-generation sulfonylureas, but may be used when needed for glycemic lowering outweighs these uncertain risks.478,500,505

Role of Glycemic Control

Hyperglycemia in diabetes mellitus is associated with increased risk of heart failure. A secondary analysis from the UKPDS showed an adjusted rate of heart failure of 2.3 events/100 person-years among patients with Hba1c levels of <6% in comparison with 11.9 among those with Hba1c levels >10%.30 Among 48 858 patients with predominantly type 2 diabetes mellitus, each 1% increase in Hba1c is associated with an 8% increased relative risk of heart failure; a similar relationship has been observed among 20 985 patients with type 1 diabetes mellitus (30% increased relative risk of heart failure per 1% increase in Hba1c).506

Despite a consistent association between hyperglycemia and heart failure, no causal relationship has been proven. Studies have failed to consistently demonstrate a relationship between blood glucose or insulin levels and left ventricular function.507,508 Although the ORIGIN trial targeting normal fasting plasma glucose levels for >6 years showed a trend toward decreased risk of heart failure hospitalization in the insulin glargine group,347 most trials have failed to show a relationship between strict glycemic control and reductions in heart failure in diabetes mellitus.211,334,336 The optimal glycemic level in diabetes mellitus patients with heart failure thus remains unclear and warrants further investigation.

Considerations for the Management of Concurrent Heart Failure and Diabetes Mellitus

The prevalence of patients with concomitant heart failure and diabetes mellitus is high, and providers should be aware of both restrictive and dilated forms of diabetic cardiomyopathy. Although standard heart failure guidelines for the general population should be followed when treating heart failure in patients with diabetes mellitus, the converse is not true: careful selection of medications is necessary in the management of diabetes mellitus in heart failure patients. In particular,
inhibition of SGLT2 with empagliflozin appears associated with a reduction in heart failure hospitalizations, making this a preferred therapy if otherwise tolerated, whereas thiazolidinediones should be avoided in patients with severe heart failure symptoms and used with caution in mildly symptomatic patients. Metformin may be used cautiously in heart failure patients with stable renal function and adequate renal perfusion. To date, there has not been any clear signal for heart failure benefit with incretin-based treatment, and there may even be an excess risk for heart failure hospitalization related to some DPP-4 inhibitors. Thus, heart failure risk differs across diabetes mellitus therapeutic classes, and additional prospective study is required to fully understand potential drug effects in this unique population.

What Is on the Horizon?

A number of new approaches for glucose lowering are under development and may provide agents with dual benefit for diabetes mellitus and the diabetic heart. Additionally, drugs that are developed for cardiovascular risk reduction may also lower glycemia. In the meantime, cardiovascular outcome trials will provide useful information on cardiovascular safety of use of diabetes mellitus drugs in patients with established heart disease or at high risk for events and additional exposure, information that may reveal previously unrecognized positive or negative effects. These trials may help to better address the question of the impact of specific glucose-lowering drugs and pharmacological class agents on the diabetic heart.

Conclusions

The long-term treatment of diabetes mellitus is challenging because of diverse goals: to address metabolic derangements and to reduce risks for both micro- and macrovascular adverse outcomes. Management of hyperglycemia has resulted in substantial reductions in risks for retinopathy with associated preservation of vision, and nephropathy with prevention of end-stage renal disease when combined with aggressive blood pressure control. Progress in prevention and amelioration of these microvascular complications has conversely resulted in a shift in the major causes of long-term morbidity and mortality in diabetes mellitus, which now consists of cardiovascular risk with associated ischemic heart disease, ischemic stroke, peripheral artery disease, and congestive heart failure. Diabetes mellitus clearly exacerbates mechanisms of atherosclerosis and heart failure. Unfortunately, these mechanisms are not adequately fully modulated or addressed by focusing solely on optimal glycemic control. Fortunately, aggressive management of cardiovascular risk factors, particularly lowering of LDL cholesterol concentration and blood pressure along with glycemic management, provides substantial improvements in cardiovascular outcomes. Therefore, we prioritize recommendations for management of cardiovascular and heart failure risk to focus on the most effective therapies, as summarized in Table 1.

Multiple areas of further investigation remain. Potential cardiovascular benefits versus risks of new glucose-lowering agents and timing of (early or prolonged) glucose-targeting interventions are incompletely understood. Evidence for a more effective antiplatelet regimen than aspirin in moderate to high risk patients with diabetes mellitus without ischemic heart disease is necessary. Recommended blood pressure goals are also not fully evidence-based, and the role of new potent lipid-lowering therapies (PCSK9 inhibitors) and lipid-lowering drugs that target triglycerides and HDL cholesterol needs further study. Another unaddressed issue is the ultimate risk–benefit ratio for polypharmacy that occurs when physicians add multiple drugs to achieve an optimal level of glycemic control and cardiovascular risk management. These are pragmatic concerns wherein the use of multiple medications can result in less overall medication compliance and increased risk of drug–drug interactions. Although the overall management of diabetes mellitus has improved substantially over the past 2 decades, there is a large unmet need for cardiovascular prevention.

Acknowledgments

We are grateful for collaborations and conversations with colleagues over the years regarding this and related topics. We thank Patrick Lane for his assistance drafting the figures. Dr Goldfine acknowledges the enrichment core of the Joslin Diabetes Research Center P30 DK036836. We also thank the Circulation editors and peer reviewers for their critical appraisal and comments, and the staff for their assistance with preparation of this manuscript.

Disclosures

Dr Hiatt receives grant support from the AstraZeneca, Bayer, GSK, and Janssen, and he serves as a consultant for Kowa. Dr Goldfine receives grant support from the National Institutes of Health, the American Diabetes Association, and Cleveland Clinic sponsored by Ethicon and Coviden. She receives supplies from Amneal Pharmaceuticals, Novo Nordisk, Lifescan, a Division of Johnson and Johnson, and Nestle, Inc. She is a site investigator for Xoma and DiaSome, and institutional consultant to Kowa. The other authors report no conflicts.

References

Cardiovascular Disease in Diabetes Mellitus


Azone Clinical Trial In macroVascular Events: a randomised controlled trial. PROspective pioglitazone Clinical Trial In macroVascular Events (PROactive Study (PROspective pioglitazone Clinical Trial In macroVascular Events)). Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial In macroVascular Events). Circulation. 2006;49:1049–1063. doi: 10.1007/s00125-006-0156-0.


2016;374:122. doi: 10.1016/j.metabol.2014.08.010.


2016;374:122. doi: 10.1016/j.metabol.2014.08.010.


2016;374:122. doi: 10.1016/j.metabol.2014.08.010.

2003;2012:2349–2350. doi: 10.1161/CIRCULATIONAHA.111.018259.


2016;374:122. doi: 10.1016/j.metabol.2014.08.010.

2001;286:327–334. doi: 10.1161/01.CIR.0000131511.50734.44.


2016;374:122. doi: 10.1016/j.metabol.2014.08.010.

2001;286:327–334. doi: 10.1161/01.CIR.0000131511.50734.44.


Cardiovascular Disease in Diabetes Mellitus


by guest on November 18, 2017 http://circ.ahajournals.org/ Downloaded from

JK, McAlister FA. Comparative safety and effectiveness of sitagliptin
Eurich DT
Currie CJ, Diabetes Obes Metab


356. Deleted in proof.


397. Tribouilloy C, Rusinaru D, Mahjoub H, Tartiere JM, Kesri-Tartiere L, Godard S, Pelletier M. Prognostic impact of diabetes mellitus in patients


Cardiovascular Disease in Diabetes Mellitus


Low Wang et al


Low Wang et al


Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus – Mechanisms, Management, and Clinical Considerations
Cecilia C. Low Wang, Connie N. Hess, William R. Hiatt and Allison B. Goldfine

Circulation. 2016;133:2459-2502
doi: 10.1161/CIRCULATIONAHA.116.022194

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2016 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/133/24/2459

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/